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Anxiety and anxiety-related disorders are common psychiatric disorders that are responsible 
for high disease burden. The pathogenesis of anxiety involves dysfunction in the limbic brain 
regions including the amygdala, prefrontal cortex, and hippocampus. The current 
pharmacological treatments for anxiety target the modulation of the activity monoamine 
neurotransmitters such as dopamine, serotonin, gamma-aminobutyric acid, norepinephrine and 
glutamate. These neurotransmitters are key in the regulation of the maladaptive responses of 
anxiety. Primary pharmacotherapies demonstrate limitations in drug efficacy as well as adverse 
side effects, highlighting the need for novel therapeutics for anxiety and anxiety-related 
disorders. Cannabidiol (CBD), a non-psychoactive cannabinoid from the Cannabis sativa 
plant, has been considered a potential anxiolytic treatment as a result of its interaction in the 
endocannabinoid system, which regulates synaptic plasticity and neuronal activity implicated 
in the anxiety response.  The therapeutic potential of CBD against neuropsychiatric disorders 
have been reported in preclinical and clinical studies. Since the global increase in cannabis 
legalization, there remains a need to supplement the available literature related to the neural 
effect of cannabis use on behavioural, neurochemical and biochemical changes. There are gaps 
in the knowledge of the pharmacokinetics and behavioural effects of CBD. This study will 
contribute to increasing the knowledge of the effect of cannabis on neurotransmitters and 
molecular changes in the brain.  
In this thesis, chapter 1 is a literature review focusing on the neurobiology and pharmacological 
treatments of anxiety, cannabidiol as a treatment for anxiety, and the neurotransmitters and 
genes implicated in anxiety. In addition to this, chapter 1 also reviews the theory of the 
experimental processes performed in this study. Chapter 2 is the publication “Evaluation of 
the use of cannabidiol in the treatment of anxiety related disorders by assessing changes 
in neurotransmitter levels and expression of CREB/BDNF in the rodent brain” submitted 
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1. Anxiety  
Anxiety is characterized by an emotional response that occurs in anticipation of potential 
threats or dangers (Sartori & Singewald, 2019). Anxiety is an incessant feeling of dread, 
trepidation and imminent disaster (Kaur & Singh, 2017; Pilkington, 2010). Most people 
experience anxious feelings when faced with stress, however this anxiety is adaptive to inform 
and prepare the person for the latent threat (Sartori & Singewald, 2019). Anxiety is deemed 
pathological when it becomes uncontrollable, persistent and maladaptive (Sartori & Singewald, 
2019). According to the World Health Organisation, anxiety disorders are estimated to have a 
global prevalence of 3.6 % and is more common in females (4.6 %) than in males (2.6 %) 
(WHO, 2017). In 2017, there were 1 768 851 reported cases of anxiety disorders in South 
Africa, which represents 3.4 % of the national population (WHO, 2017). The disease burden 
of anxiety disorders is reported as 2.8% of the total years living with disability in the South 
African population (WHO, 2017).  
Anxiety disorders may arise from a multifaceted set of risk factors including genetics, brain 
chemistry, personality and life events (Kaur & Singh, 2017).  Anxiety disorders are categorized 
by the International Statistical Classification of Diseases and Related Health Problems into 
generalized anxiety disorder (GAD), social anxiety disorder (SAD), and panic disorder (PD) 
(Kogan et al., 2016; Reed et al., 2019). Social Anxiety Disorder, also known as social phobia, 
is a common anxiety disorder characterized by an individual fearing and avoiding the scrutiny 
by others (Stein & Stein, 2008). Patients with SAD have a persistent fear in social situations 
with exposure to unknown people (Stein & Stein, 2008). The individuals experience intense 
emotional and physical anxiety symptoms which may lead to them avoiding social situations, 
which could interfere with their personal life (Stein & Stein, 2008). Panic disorder is diagnosed 
by repeated unpredicted panic attacks, anxiety about imminent panic attacks, or significant 
behavioural changes because of the panic attacks (Craske & Barlow, 2014). Generalized 
Anxiety Disorder is one of the most common and debilitating conditions. GAD is described by 
an uncontrollable, multifocal chronic worry that persistently occurs for periods of longer than 
6 months (Stein & Sareen, 2015).  
Patients with anxiety display a variety of cognitive, physiological and behavioural symptoms 
(Lang & Schlien, 1968). The cognitive factor of anxiety is associated with cognitive distortions 
in the components of attention, interpretation, and memory for information processing (Hollon 
& Beck, 2013; Kaur & Singh, 2017). The physiological symptoms of anxiety incorporate 
autonomic or somatic sensations, including sleep avoidance, insomnia, headaches, muscle 
2 
 
tension, gastrointestinal problems nightmares, heart palpitations, tachycardia and shortness of 
breath (Alfano, Ginsburg, & Kingery, 2007). The behavioural component of anxiety indicates 
the actions performed by an individual to prevent exposure to the feared stimuli. The 
behavioural symptoms involve avoidance of a particular stimuli or situation by the individual, 
thus impairing ones daily routines as well as family, academic and social functions (Hayes, 
Villatte, Levin, & Hildebrandt, 2011). Anxiety related disorders are accompanied by 
psychological symptoms including depression, alcohol and substance abuse (Sareen et al., 
2006; Stein & Sareen, 2015). Anxiety-related disorders are associated with a decreased sense 
of well-being, elevated rates of unemployment and relationship breakdown, and increased 
suicide risk (Stein & Sareen, 2015)  
1.1.  Neuronal circuitry of anxiety  
There are many brain regions implicated in the identification and modulation of adverse 
emotional stimuli and in the generation of cognitive, behavioural or somatic responses to the 
stimuli (Nuss, 2015). Human and rodent studies have contributed to identifying brain regions 
implicated in anxiety by developing worry, tension and apprehension due to an aversive 
stimulus (Duval, Javanbakht, & Liberzon, 2015). The amygdala nuclei situated within the 
temporal lobe and is considered as the central orchestra in the control of anxiety related 
responses (Linsambarth, Moraga-Amaro, Quintana-Donoso, Rojas, & Stehberg, 2017; Nuss, 
2015). The basolateral amygdala complex (BLA) and the central amygdala (CeA), within the 
central nucleus, are two groups of nuclei that are critical in anxiety (Etkin, 2009). The BLA 
receives incoming information and determines the threat value of potentially negative 
emotional signals from the thalamus and the sensory association cortex (Davis & Whalen, 
2001; Nuss, 2015). The CeA is vital in the species-specific defensive responses associated with 
fear (Davis & Whalen, 2001).  
The CeA is directly activated by the BLA through an excitatory glutamatergic pathway 
(Pitkänen, Savander, & LeDoux, 1997). The BLA initiates a relay of inhibitory GABAergic 
interneurons situated between the BLA and the CeA, which employs an inhibitory effect on 
the CeA (Royer, Martina, & Pare, 1999). The somatic manifestation of anxiety occurs due to 
activation of the GABAergic neurons from the CeA to the hypothalamus and brainstem 
(Jongen‐Rêlo & Amaral, 1998). Inhibitory GABAergic neuron projections from the CeA to the 
locus coeruleus (LC) and other forebrain nuclei may be involved in anxiety-related dysphoria 
(Forster, Novick, Scholl, & Watt, 2012). The bed nucleus of the stria terminalis (BNST), 
adjacent to the amygdala, is activated by the inhibitory neurons from the BLA which also may 
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have a role in dysphoria (Forster et al., 2012; Linsambarth et al., 2017). Studies suggest that 
the pharmacological activation of the BLA and CeA are anxiogenic, whereas its inhibition is 
anxiolytic (Flores-Gracia et al., 2010; Truitt, Johnson, Dietrich, Fitz, & Shekhar, 2009). 
 
Figure 1: Structure of amygdala involved in the regulation of anxiety (sourced from 
(Mah, Szabuniewicz, & Fiocco, 2016). 
Forebrain areas, including the medial prefrontal cortex (PFC) and the anterior cingulate cortex 
(ACC) are activated concurrently with the amygdala during the presence of an emotional 
stimuli (Figure 1) (Kober et al., 2008; Mah et al., 2016). These areas receive and convey 
excitatory glutamatergic projections to and from the BLA (Kober et al., 2008). The expression 
of anxiety is controlled by the PFC through the changes of neuronal activity in the BLA (Etkin, 
2009; M. J. Kim et al., 2011). The neuronal circuitry of anxiety includes bottom-up activity 
from the amygdala, showing the presence of potentially threatening stimuli, and top-down 
control mechanisms originating in the PFC, signalling the emotional salience of stimuli as 
depicted in Figure 2 (Nuss, 2015). It is critical in understanding the factors that control these 
bottom-up/top-down mechanisms so that more effective anxiolytic interventions can be 





Figure 2: Neuronal circuitry of anxiety disorders highlighting the role of the amygdala 
(adapted from (Nuss, 2015). 
Key: orange arrow: negative emotional stimulus received from thalamus and sensory 
association cortex; green arrow: excitatory glutamatergic pathways; blue arrows: GABAergic 
inhibitory neurons are activated leading to the somatic manifestation of anxiety in the 
brainstem, hypothalamus and basal forebrain  
Abbreviations: ACC, anterior cingulate cortex; PCC, posterior cingulate cortex; BLA, 
basolateral amygdala; BNST, bed nucleus of the stria terminalis; CeA, central nucleus of the 
amygdala; PFC, prefrontal cortex. 
2. Pharmacological treatment of anxiety  
The treatment of anxiety disorders should include psychological therapy, pharmacotherapy, or 
a combination of both (Bandelow, Michaelis, & Wedekind, 2017). The current 
pharmacological treatments include serotonin reuptake inhibitors, benzodiazepines, 
monoamine oxidase inhibitors, tricyclic antidepressant (TCA) drugs, and partial 5-
hydroxytryptamines (5-HT) 1A receptor agonists (Bandelow et al., 2017). The serotonin 
reuptake inhibitors (SSRIs) and the serotonin norepinephrine reuptake inhibitors (SNRIs) are 
the recommended first-drugs as a result of their positive benefit to risk balance ratio (Bandelow 
et al., 2017; Sartori & Singewald, 2019). SSRIs produce side effects such as jitteriness at the 
onset of therapy, gastrointestinal problems, insomnia, and sexual dysfunction which may or 
may not improve over time (Stübner et al., 2018). The TCAs are second-generation drugs 
which include imipramine and clomipramine (Thanacoody & Thomas, 2005). The TCAs have 
5 
 
a higher frequency of adverse effects and tolerability issues in comparison to the SSRIs and 
SNRIs (Bandelow et al., 2017). One of the shortcomings of the SSRIs and the TCAs is the 
delayed therapeutic action, rendering antidepressants ineffective as an acute anxiolytic 
treatment (Gomez et al., 2018). Benzodiazepines are efficacious in treating GAD, an acute 
anxiety disorder, but produces a range of side effects in long-term treatment, for example, 
dependence, withdrawal symptoms, impaired cognition and overdose deaths (Baandrup et al., 
2018; Bachhuber, Hennessy, Cunningham, & Starrels, 2016). Therefore there is a need to 
develop or investigate novel pharmacological anxiolytic treatments due to the many 
shortcomings of the current treatments including increased cost of drug development, a 
diminished rate of successful drug discovery and development and long-term adverse side 
effects (Guina & Merrill, 2018; Nutt & Attridge, 2014; Sartori & Singewald, 2019). 
3. Cannabis sativa 
Cannabis sativa, also commonly known as marijuana, is a plant with a wide range of medicinal 
properties which has been extensively used throughout human history (Zou & Kumar, 2018). 
The Cannabis plant is classified into three species, C. sativa, C. indica and C. ruderalis 
(Akatan, 2012). The extracts of this ancient medicinal plant were reported to be first used as 
cramp and pain relief in China as early as 6000 BC (Mechoulam, 1986). Cannabis has a wide 
range of therapeutic uses including anti-inflammation, anti-nociception, anti-emetic and 
anticonvulsant activities (Iversen, 2003; Mechoulam, 1986; Wallace, Wiley, Martin, & 
DeLorenzo, 2001). However, the clinical application of the therapeutic action of Cannabis is 
limited due to the recreational use (Zou & Kumar, 2018). Cannabis contains in excess of 400 
chemical constituents, including cannabinoids and other psychoactive phytochemicals, which 
are responsible for its biological effects (Atakan, 2012). Cannabinoids are found in the stalk, 
leaves, flowers and seeds of the cannabis plant (C. H. Ashton, 2001). Delta-9-
tetrahydrocannabinol (Δ-9-THC) is one of the principle psychoactive component of 
approximately 70 phytocannabinoids identified in the plant (Atakan, 2012; Pacher, Bátkai, & 
Kunos, 2006). Some of the other identified phytocannabinoids also have individual biological 
effects which may mediate the psychoactive effects of THC (Mechoulam & Parker, 2013). It 
has been suggested in preclinical studies that the individual effects of phytocannabinoids are 
multiphasic and dose-dependent, which can be demonstrated by Δ-9-THC which has anxiolytic 
effects at low doses and anxiogenic effects at higher doses (Rey, Purrio, Viveros, & Lutz, 
2012). There are minor cannabinoids which also display a range of biological activities such 
as cannabigerol which has antibacterial activity, cannabinol has sedative properties, and 
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tetrahydrocannabivarin has antiepileptic effects (Aizpurua-Olaizola et al., 2014), however the 
therapeutic roles of many of them remain unknown. 
3.1. Cannabidiol (CBD) 
Cannabidiol is a metabolic by-product and major cannabinoid of Cannabis sativa (Citti et al., 
2018). Cannabidiol, shown in Figure 3, is the principle non-intoxicating component of 
Cannabis sativa, which is produced in high concentrations in the plant making up 
approximately 40% of the total cannabinoid content (Deiana et al., 2012). In contrast to THC, 
cannabidiol does not exhibit psychotropic effects (Alline Cristina Campos, Moreira, Gomes, 
Del Bel, & Guimaraes, 2012). Cannabidiol is a promising therapeutic agent which can be 
observed in its anxiolytic (Crippa et al., 2009), anti-psychotic (Moreira and Guimaraes, 2005), 
anti-inflammatory (Juknat, Rimmerman, Levy, Vogel, & Kozela, 2012), anti-convulsant 
(Wallace et al., 2001), and immunomodulatory (Costa, Trovato, Comelli, Giagnoni, & 
Colleoni, 2007) properties of CBD. The properties of cannabidiol allow it to be utilized in the 
treatment of a wide range of psychiatric and non-psychiatric disorders such as psychosis, 
anxiety and depression(Alline Cristina Campos et al., 2012). The anxiolytic and anti-psychotic 
effects of CBD can offset the anxiety and psychotomimetic effects induced by THC (Douglas 
Lee Boggs, Peckham, Boggs, & Ranganathan, 2016). 
 
Figure 3: Structure of cannabidiol (CBD) 
 
Previous literature has suggested that this non-psychotomimetic compound has a relatively low 
affinity for cannabinoid (CB) receptors (Pertwee, 1997; Pertwee et al., 2010). However, studies 
by (Thomas et al., 2007) reported that CBD has the ability to act as a partial antagonist at 
cannabinoid-1 (CB1) receptors and as an inverse agonist at cannabinoid-2 (CB2) receptors.  
Cannabidiol has a complex pharmacological profile as more than 20 different mechanisms of 
action has been described (Douglas L Boggs, Nguyen, Morgenson, Taffe, & Ranganathan, 
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2018; Deiana et al., 2012). There are two well-researched mechanisms of action by which CBD 
exerts its antipsychotic effects: the facilitation of endocannabinoid signalling, and the 
administration of an exogenous CB receptor agonist. There is an increase in research depicting 
the beneficial effects of cannabidiol in the brain, concluding CBD as a promising novel therapy 
for various neurological disorders. 
3.2 Delta-9-tetrahydrocannabinol 
The discovery of THC resulted in the generation of a range of synthetic cannabinoids that are 
similar in structure to phytocannabinoids, which finally led to the identification and successful 
cloning of the CB1 receptor, and the CB2 receptor (Pertwee et al., 2010). THC, depicted in 
Figure 4, is a partial agonist of the CB1 and CB2 receptors, that are G protein coupled receptors 
which are part of the endocannabinoid system (Atakan, 2012). THC produces hypothermia, 
hypoactivity, spatial and verbal short-term memory impairment, in a dose-dependent manner 
(Hayakawa et al., 2008). It is suggested that the pharmacological effects of Δ -9-THC can be 
potentiated by CBD via a CB1R-dependent mechanism (Hayakawa et al., 2008). Delta-9-THC 
has the ability to activate the CB1 and CB2 receptors, similar to the endocannabinoids 
(Pertwee, 2008). THC produces in vivo effects in healthy rodents via the activation of the CB1 
receptors which inhibit the ongoing neurotransmitter release (Howlett et al., 2002; Pertwee, 
2008). In mice, Δ-9-THC generates a ‘tetrad’ of effects including the suppression of locomotor 
activity, hypothermia, immobility during the ring test and antinociception in the tail-flick test 
(Pertwee, 2008). In a study performed by (Atakan, 2012), it was reported that Δ-9-THc caused 
transient psychotic symptoms, augmented the levels of anxiety, intoxication and sedation in 
healthy volunteers whilst CBD had no significant effect on these parameters. During brain 
imaging, THC reduced the action of brain regions that typically mediate response inhibition, 
whilst CBD controlled activity in regions not implicated during verbal learning tasks 
(Borgwardt et al., 2008).  
 
Figure 4: Structure of delta-9-tetrahydrocannabinol 
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4. The Endocannabinoid System 
The endocannabinoid system is responsible for mediating the physiological changes, such as 
motor function, pain perception, cognition, appetite, and sleep cycles, that occur after cannabis 
administration (Mechoulam & Parker, 2013). This system is comprised of endogenous 
cannabinoids (endocannabinoids), anandamide (AEA) and 2-arachidonoyl-glycerol (2-AG), 
cannabinoid-1 receptors and cannabinoid-2 receptors, and enzymes which synthesize and 
degrade endocannabinoids (Dhopeshwarkar & Mackie, 2014). Anandamide is synthesized by 
the enzyme, N-acylphosphatidylethanolamine-selective phospholipase D, and degraded by 
fatty acid amide hydrolase (FAAH) (De Aquino et al., 2018). The other endocannabinoid, 2-
arachidonoylglycerol, is synthesized by diacylglycerol lipase and monoacylglycerol, whereas 
2-arachidonoylglycerol hydrolase degrades 2-AG (De Aquino et al., 2018). These 
endocannabinoids differ from other neurotransmitters as they are synthesized on demand which 
is initiated by the activation of G-protein- coupled receptors or depolarization (Mechoulam & 
Parker, 2013). The precursors of endocannabinoid are found in the lipid membranes of post 
synaptic neurons (De Aquino et al., 2018; Mechoulam & Parker, 2013). Cannabinoids interact 
with cannabinoid receptors, as well as, other G protein-coupled receptors, nuclear receptors 
and ion channels (Howlett et al., 2002). The endocannabinoids act as endogenous agonists of 
the cannabinoid receptors and have varying intrinsic efficacies to the cannabinoid receptors 
(Lu & Mackie, 2016). Anandamide is a low efficacy agonist at CB1 receptors and an extremely 
low efficacy agonist at CB2 receptors (Lu & Mackie, 2016; Luk et al., 2004). 2-Arachidonoyl 
glycerol is a high efficacy agonist at both CB1 and CB2 receptors (Gonsiorek et al., 2000; Luk 
et al., 2004).  
The cannabinoid receptors are members of the superfamily of G-protein-coupled receptors 
(GPCR’s) which mainly couple to Go and Gi protein classes(Howlett et al., 2002). Hence, the 
activation of these receptors exerts various effects on cellular physiology such as the inhibition 
of adenylyl cyclases and voltage dependent calcium channels, as well as the activation of many 
MAP kinases (Howlett et al., 2002). The regulation of cannabinoids is primarily based on 
retrograde signalling where the endocannabinoids are synthesized and released on demand, 
which differs from other neurotransmitters that are produced in advanced and stored in vesicles, 
from post synaptic sites to active the CB receptors on the presynaptic membranes in neurons 
(Figure 5) (Alger, 2002; Navarro et al., 2016). The synthesis of endocannabinoids is promoted 
by depolarization or the activation of the G-protein-coupled receptors (De Aquino et al., 2018). 
9 
 
Exogenous cannabinoids have a distinction from endocannabinoids as they are metabolized 












Endocannabinoids act as neuromodulators that inhibit the release of other neurotransmitter 
systems such as GABA and glutamate. The endocannabinoids are retrogrades which are 
released on demand from the postsynaptic sites and exert their effects by binding to CB1Rs on 
the presynaptic membrane. The CB receptors are activated and inhibit the release of 
neurotransmitters through the various ion channels. The interaction between endocannabinoid 
system with multiple neurotransmitters, such as acetylcholine, dopamine, GABA, serotonin, 
glutamate, and norepinephrine, mediates many pharmacological effects of cannabinoids. 
4.1 Cannabinoid-1-receptor 
The CB1 receptors are the most abundant cannabinoid receptors and are primarily expressed 
in the central and peripheral nervous system. These receptors have a fundamental role in the 
mammalian central nervous system (CNS) in regulating neuronal activity as endocannabinoids 
rely on the receptors for higher brain function activity (Marcu & Schechter, 2016; Navarro et 
al., 2012). In rodent brain models, CB1 receptors are found in higher densities in the basal 
ganglia, substantia nigra, globus pallidus, cerebellum and hippocampus (Mechoulam & Parker, 
2013). CB1 receptors are also expressed in the heart, bones, lung, thyroid liver, uterus, 




testicular tissue and the vascular endothelium (Pertwee, 2006; Russo & Guy, 2006). CB1 
receptors are located at both the GABAergic and glutamatergic terminals of the central and 
peripheral neurons, suggesting their involvement on GABA and glutamate neurotransmission 
and both inhibitory and excitatory activity (Atakan, 2012; Howlett et al., 2002; Mechoulam & 
Parker, 2013). They are also found in the central nervous system of the brain areas that are 
related to the body’s stress response (Atakan, 2012; Kaur & Singh, 2017). These brain areas 
include the central amygdala, basal ganglia, limbic system, hippocampus, frontal cortex, 
substantia nigra and the cerebellum (Pertwee, 2006). In the brain, CB1 receptors mediate 
inhibitory actions by the ongoing release of excitatory and inhibitory dopaminergic, gamma-
aminobutyric acid (GABA), glutamatergic, serotoninergic, noradrenalin and acetylcholine 
neurotransmitter systems (Atakan, 2012). The involvement of the neurotransmitter systems and 
the high density of CB1 receptors in the sensory and motor brain regions contribute to the 
motor movement, pain perception and cognition functions (Howlett et al., 2002). The activation 
of CB1 receptors results in a decline in the accumulation of cyclic adenosine monophosphate 
(cAMP), subsequently the inhibition of cAMP-dependent protein kinase (PKA) (Mechoulam 
& Parker, 2013). The potential of CB1 receptors as targets for CNS diseases are limited by the 
psychotropic side effects of its natural agonists, such as delta-9-tetrahydrocannabinol, on the 
animal models (Navarro et al., 2012). Therefore, there is an increasing research performed on 
CB2 receptors as targets for diseases of the CNS (Navarro et al., 2012). 
4.2 Cannabinoid-2 receptors 
The CB2 receptors are abundantly expressed on the surface of cells involved in the peripheral 
immune system (Atkinson & Abbott, 2018). In the brain, the CB2 receptors are localized to 
some extent in the neurons of the brainstem, the cerebellum, internal and external segments of 
the globus pallidus, substantia nigra, and in the microglial cells (Atkinson & Abbott, 2018; 
Lanciego et al., 2011; Stella, 2004). However, the CB2 receptors are expressed at a lower level 
compared to CB1 receptors in the central nervous system (J. C. Ashton, Friberg, Darlington, & 
Smith, 2006; Mechoulam & Parker, 2013). Consequently, there are fewer side effects that are 
expected when drugs are targeting CB2 receptors, which has limited expression in the CNS, 
compared to drugs targeting the abundantly expressed CB1 receptors in the CNS (Navarro et 
al., 2016). CB2 receptors are upregulated in the activated microglial cells in a variety of CNS 
diseases, making it a promising candidate in diseases with neuroinflammatory components 
(Navarro et al., 2016). There is some controversy pertaining to the degree of CB2 receptor 
expression in resting verses activated microglial cells as there is a difference in the phenotypes 
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of microglial that are filtered from blood into the CNS, and in resident microglial which 
becomes activated by accumulation of proteins (Navarro et al., 2016). An improved 
understanding of the expression and the role of CB2 receptors in the various microglial 
phenotypes will assist in designing CB2 receptor ligands with the potential to induce the anti-
inflammatory-skewed phenotypes (Franco & Fernandez-Suarez, 2015). A review by 
(Mechoulam & Parker, 2013) discussed the possibility of CB2 receptors as a component of a 
general protective system of the mammalian body, particularly the immune system. The CB2 
receptors are also involved in CNS inflammation which is an increasingly researched aspect of 
the pathophysiology of schizophrenia (Müller, Weidinger, Leitner, & Schwarz, 2015).  
Cannabinoids, such as cannabidiol, that target CB2 receptors have potential therapeutic 
properties such as the preservation of neuronal integrity and survival (Atwood, Straiker, & 
Mackie, 2012). Accordingly, cannabidiol has a promising potential in pain, and acute and 
chronic neuroinflammatory conditions (Micale, Mazzola, & Drago, 2007). The neuroprotective 
potential of the CB2 receptor-targeting cannabinoids is mediated by their various locations in 
the CNS (Chung et al., 2016; Navarro et al., 2016). This enables the cannabinoids to selectively 
activate the CB2 receptors to apply a selective control over the particular functions performed 
by these cells in protection, degeneration and repair (Fernández-Ruiz et al., 2014). The 
pharmacological action of anxiolytic treatments, including cannabidiol and standard drugs such 
as benzodiazepines, implicate the neurotransmitters within the central nervous system 
(Bandelow et al., 2017; Sartori & Singewald, 2019).  
5. Neurotransmitters and anxiety 
Neurotransmitters (NT’s) are signalling molecules, which have vital roles in neuronal 
communications within the central nervous system (CNS) (Liu, Zhao, & Guo, 2018). Previous 
literature has reported that modifications in the quantification of NT’s in many brain regions 
involve the development of several neurodegenerative and psychiatric diseases such as 
Parkinson’s disease, Huntington’s disease, multiple sclerosis (Bandelow & Michaelis, 2015; 
Hussain, Zubair, Pursell, & Shahab, 2018). Neurotransmitters are categorized based on their 
chemical structures: (i) small molecules and (ii) neuropeptide (Liu et al., 2018). The small 
molecules consist of dopamine (DA), norepinephrine (NE), glutamate (Glu), serotonin (5-HT), 
epinephrine (EP), gamma-aminobutyric acid (GABA) and endocannabinoids (Kaur & Singh, 
2017). The neuropeptides include enkephalin, endorphin and substance P (Kaur & Singh, 
2017). The irregular functioning of neurotransmitters such as dopamine, GABA, 
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norepinephrine, serotonin, acetylcholine and, chemoreceptor activity results in anxiety (Kaur 
& Singh, 2017).   
5.1 The function of dopamine in anxiety  
Dopamine (Figure 6), is the principle catecholamine in the mammalian brain and is vital in 
various cerebral functions including reward, motor control, learning, cognition, and emotion 
(Ko & Strafella, 2012; Zarrindast & Khakpai, 2015). The dopaminergic system is also involved 
in the pathogenesis of many psychiatric and neurological disorders such as Parkinson disease 
(PD), depression, anxiety, schizophrenia, Huntington disease and behavioural/chemical 
addiction (Ko & Strafella, 2012). The dopaminergic system plays a vital role in anxiety-like 
behaviour via the transmission in the mesolimbic, mesocortical and nigrostriatal pathways 
(Melis & Pistis, 2012).  Dopamine is produced in the substantia nigra and is important in the 
reward system for anxiety (Nasehi, Mafi, Oryan, Nasri, & Zarrindast, 2011). This 
neurotransmitter is released from the substantia nigra and the VTA, via the dopaminergic 
pathways, to all brain regions involved in anxiety such as the amygdala, hippocampus, septum, 
prefrontal cortex and nucleus accumbens (Melis & Pistis, 2012; Zarrindast & Khakpai, 2015).  
 
 
Figure 6: Structure of Dopamine 
 
5.2 The function of serotonin in anxiety  
Serotonin (5-hydroxytryptamine; 5-HT) (Figure 7) is involved in the regulation of emotion 
(Kaur & Singh, 2017). This neurotransmitter system has complex and multifaceted functions 
in cognition, learning, memory and reward (Young, 2007). Serotonin has an essential role in 
the development of anxiety disorders which is modulated by its effect on the locus coerulus 
and amygdala in the brain (Graeff, 2002; Jia & Pittman, 2014). The serotonergic pathways are 
activated by components of anxiety including fear and stress (Akimova, Lanzenberger, & 
Kasper, 2009). Previous literature demonstrates an increase in 5-HT levels in the brain 
corresponds to an increase in anxiety, whereas an attenuation in the levels of 5-HT reduces 
anxiety (Murphy et al., 2013).The extensive range of actions of 5-HT neurons are regulated at 
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a series of 5-HT receptors (5-HTR) (Staes et al., 2019). In humans, genetic polymorphisms in 
the serotonin receptor subtype 1A receptor (5-HT1A receptor), 5-HT subtype 2A receptor (5-
HT2A receptor) and the 5-HT transporter (SLC6A4) are associated with anxiety disorders, 
impulsivity and neurotic personalities (Golimbet, Alfimova, & Mityushina, 2004; Gordon & 
Hen, 2004; Lesch & Gutknecht, 2005; Staes et al., 2019).  
 
Figure 7: Structure of Serotonin 
 
5.3 The function of glutamate in anxiety 
Glutamate (Figure 8), is the principle excitatory neurotransmitter ubiquitous in the mammalian 
central nervous system, specifically in the cortex and subcortical brain regions (Lujan, 
Shigemoto, & Lopez-Bendito, 2005). The glutamatergic system has pivotal roles in various 
brain functions such as, neurodevelopment, learning, information transfer, acute and chronic 
neurodegeneration, response to stress and anxiety disorders (Kew & Kemp, 2005). The actions 
of glutamate are regulated via four glutamate receptors: N-methyl-d-aspartate (NMDA), 
kainite, G protein-coupled metabotropic receptors (mGluR1-8) and a-amino-3-hydroxy-5-
methyl-4-isoxazole (AMPA) (Kew & Kemp, 2005; Zhou & Danbolt, 2014). Recent studies 
have demonstrated the important function of the glutamatergic transmission in the pathogenesis 
of anxiety disorders (Zhou & Danbolt, 2014). Glutamate excitotoxicity is the excessive 
activation of glutamate receptors that can excite nerve cells to their death, and this occurs 
during extreme stress and anxiety exposure (Zhou & Danbolt, 2014). An increase in glutamate 
results in excitotoxicity, which subsequently results in anxiety due to cell death. Anxiolysis 
can be stimulated by a reduction in endogenously released glutamate (Kaur & Singh, 2017; 





Figure 8: Structure of Glutamate 
 
5.4 The function of Gamma-Aminobutyric acid (GABA) in anxiety 
GABA (Figure 9), is a principle inhibitory neurotransmitter which is abundantly distributed 
throughout the mammalian brain (Watanabe, Maemura, Kanbara, Tamayama, & Hayasaki, 
2002). Neurons containing GABA establish interneuronal populations in the cortex regions 
(Rudy, Fishell, Lee, & Hjerling‐Leffler, 2011). The neurotransmission of GABA is believed to 
strongly modulate excitatory neurotransmission, regulate the processing of information and 
neuroplastic events through polysynaptic communication with glutamatergic neurons (Kelsom 
& Lu, 2013)  This neurotransmitter system is considered to be the core of the regulation of 
anxiety and is the primary target of anxiolytic drugs and benzodiazepines (Lydiard, 2003). The 
regulation of neuronal activity is influenced by GABA controls the excitability states in brain 
areas (Lydiard, 2003). Anxiety disorders are linked to the dysfunction of the GABA system 
(Lydiard, 2003). The pathogenesis of anxiety has been associated with the GABAergic brain 
regions such as the amygdala, hippocampus and hypothalamus(Kalueff & Nutt, 2007). The 
onset of anxiety in animal models were correlated with a decrease in the expression of GABA 
receptors and the synthesis of GABA (Mei et al., 2005). Clinical and pre-clinical studies have 
shown that anxiolytic effects are produced from positive modulators of GABA receptors, 
whereas the negative modulators cause anxiogenic activity (Nutt, 2001). An early study by 
(Study & Barker, 1981) proved that GABA receptors are a target for benzodiazepines, which 
augment the inhibitory action of GABA.   
 




5.5 The function of norepinephrine in anxiety  
Norepinephrine (NE) (Figure 10) is an essential monoamine neurotransmitter that has broad 
effects across brain areas to regulate arousal and environmental and internal stress responses 
(Goddard et al., 2010). The central norepinephrine system is labelled as a modulator with 
anxiogenic or anxiolytic effects which changes according to acute of chronic conditions of 
stress (Goddard et al., 2010). Norepinephrine neurons are distributed in small clustered groups 
in the brainstem, including the locus coeruleus (LC) (Pacak & Palkovits, 2001). The LC-NE 
system provides an optimal and adaptable mechanism for offsetting vigilance with focused 
attention based on the novelty of environmental stimuli (Goddard et al., 2010). The response 
of norepinephrine to acute and chronic stress involve neuroendocrine and autonomic 
adaptations (Goddard et al., 2010). According to early literature, the activity of LC-NE 
neuronal firing transpires in phasic bursts whilst responding to an acute threat signal 
(Abercrombie & Jacobs, 1987). An unexpected surge in the autonomic and neuroendocrine 
response can elicit acute panic attacks in humans (Koob, 1999). Prolonged and repeated stress 
may result in the development of anxiety. The amygdala and the prefrontal connections are 
vital as neural substrates of fear and anxiety states in animals and humans (Bishop, 2007). 
Under chronic stress, the NE system activity dysregulation of various brain regions may change 
a homeostatic stress response into a pathological stress response (Goddard et al., 2010). The 
hyperactivity of norepinephrine in the CNS can cause symptoms of anxiety by the activation 
of the corticotropin-releasing factor (Martin, Ressler, Binder, & Nemeroff, 2009). 
Pharmacological treatments for anxiety disorder patients that affect the NE system result in 
anxiolytic outcomes (Goddard et al., 2010). 
 
Figure 10: Structure of Norepinephrine 
 
5.6 The function of acetylcholine in anxiety 
Acetylcholine is pivotal to the learning and memory processes in the brain. Acetylcholine 
(Figure 11) levels are regulated by stress in many brain regions. Cognitive impairment is 
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induced by an increase in cholinergic transmission as a result of the activation of presynaptic 
(nicotine) and post-synaptic (muscarinic) cholinergic receptors (Dall'Acqua, 2013). The 
hyperactivity of the brain cholinergic systems can contribute to the pathophysiology of 
depression and anxiety (Mineur et al., 2013). Clinical and pre-clinical studies have 
demonstrated that cholinergic receptor blockers can induce anti-depressant-like and anti-
anxiety-like responses (Furey & Drevets, 2006). The presynaptic nicotinic receptor facilitates 
GABAergic neurons which induced anxiety (Anderson & Brunzell, 2012). 
 
Figure 11: Structure of Acetylcholine 
 
5.7 The implication of neurotransmitters in anxiolytic treatments  
GABA agonists, or benzodiazepines, are one of the most recognized and commonly prescribed 
and anxiolytic treatments (Linsambarth et al., 2017). In the amygdala, the anxiety neuronal 
circuitry is considered to be comprised of GABAergic interneurons (Marowsky, Yanagawa, 
Obata, & Vogt, 2005; Palomares-Castillo et al., 2012).  Infusions of GABA agonists into the 
amygdala reduces fear and anxiety in many animal species, whereas GABA antagonist 
infusions upsurge fear and anxiety (Barbalho, Nunes-de-Souza, & Canto-de-Souza, 2009). This 
is supported by studies by (Moghaddam, Roohbakhsh, Rostami, Heidary-Davishani, & 
Zarrindast, 2008) and (Jiménez-Velázquez, López-Muñoz, & Fernández-Guasti, 2010), which 
demonstrated the anxiolytic effects of microinjections of GABA agonists into the basolateral 
amygdala (BLA), whilst microinjections of GABA antagonists elicited anxiogenic effects. 
Anxiolytic drugs classes, such as benzodiazepines, bind to the allosteric sites on the GABAA 
receptors which permits the precise regulation of the neuron inhibition (Mody & Pearce, 2004; 
Nuss, 2015). The inhibition of GABAergic neurons is important for the maintaining the 
equilibrium between neuronal excitation and inhibition (Mody & Pearce, 2004). During 
anxiety states, the GABAergic neuronal inhibition is downregulated (Nuss, 2015). The 
mechanism of this downregulated may be explained by fluctuations in the levels of the 
endogenous modulators of the allosteric sites and alterations in the subunit structure of the 
GABAA receptors (Nuss, 2015).  
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Mononamine neurotransmitters mutually interact with each other in the central nervous system 
(Quesseveur, M Gardier, & P Guiard, 2013). NE is essential in the regulation of the release of 
5-HT (Liu et al., 2018). Studies suggest that the 5-HT2A receptors can enhance the release of 
NE under the anxiolytic SSRIs treatment (Sullivan et al., 2005).The serotonin 5-HT1A receptor 
(5-HT1aR) is a metabotropic G protein-coupled receptor which is involved in the pathogenesis 
of anxiety and depression (Rupprecht et al., 2009). The anxiolytic effect of SSRI’s, a first-line 
clinical treatment for anxiety, is reliant on the activation of 5-HT1aR (Rupprecht et al., 2009; 
Santarelli et al., 2003). The acute anxiolytic actions of acute CBD administration are proposed 
to be mediated by 5-HT1A receptors (Alline C Campos et al., 2017). Acute and chronic CBD 
administration into brain regions such as the basal ganglia, the BNST, prelimbic PFC and the 
dorsal raphe nucleus appear to mediate CBD effects via the 5-HT1A receptors (Espejo-Porras, 
Fernández-Ruiz, Pertwee, Mechoulam, & García, 2013; Fogaça, Reis, Campos, & Guimaraes, 
2014; Gomes, Resstel, & Guimarães, 2011; Katsidoni, Anagnostou, & Panagis, 2013). This 
was supported by the 5-HT1A receptor antagonist, WAY-100635, preventing the anxiolytic 
effects of CBD administration (Alline C Campos et al., 2013; Zanelati, Biojone, Moreira, 
Guimaraes, & Joca, 2010). The mechanism of activation of 5-HT1A receptor by CBD is unclear. 
Literature suggests that the mechanism may involve a rise in 5-HT release and/or reuptake 
inhibition, or an indirect formation of heterodimers consisting of 5-HT1A and other receptors, 
such as CB1 (Linge et al., 2016; Mato et al., 2010). 
6. Gene expression and anxiety 
Brain-derived neurotrophic factor (BDNF) is a neurotrophin that is involved in many affective 
disorders including depression and anxiety (Bergami, Berninger, & Canossa, 2009; 
Martinowich, Manji, & Lu, 2007). BDNF has a neuroprotective effect, supports the 
proliferation, differentiation, maturation and survival of neurons in the nervous system, as well 
as stimulates and regulates neurogenesis (Binder & Scharfman, 2004; Huang & Reichardt, 
2001). BDNF levels are reduced in neurodegenerative diseases including multiple sclerosis, 
Parkinson’s diseases, depression and anxiety (Bathina & Das, 2015; Scalzo, Kümmer, Bretas, 
Cardoso, & Teixeira, 2010).  BDNF enhances neurogenesis via the tyrosine kinase B (TrkB) 
receptor, which activates a variety of downstream signalling pathways (Palomares-Castillo et 
al., 2012). The serum and plasma BDNF levels are reduced in patients with an anxiety disorder 
compared to patients without an anxiety disorder (Dell'Osso, Buoli, Baldwin, & Altamura, 
2010; dos Santos et al., 2011; Maina et al., 2010; Ströhle et al., 2010; Wang, Mathews, Li, Lin, 
& Xiao, 2011). The expression of BDNF messenger RNA (mRNA), in the hippocampus and 
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prefrontal cortex, can be considerably increased by multiple classes of anti-depressant and 
anxiolytic treatments (Duman & Monteggia, 2006). CBD induces anti-depressant-like effects 
associated with elevated BDNF levels in the medial prefrontal cortex (mPFC) and 
hippocampus (Sales et al., 2019). The effects may be related to rapid changes in synaptic 
plasticity in the mPFC through activation of the BDNF-TrKB signalling pathway (Sales et al., 
2019).  
Cyclic AMP response element binding protein activation (CREB) is one of the long-term 
transcriptional factors that is considered to mediate the effects of anti-depressants on BDNF 
expression (Malberg & Blendy, 2005). CREB is well-known for its implication in memory and 
learning (Carlezon Jr, Duman, & Nestler, 2005; Herdegen et al., 1997). Hippocampal CREB 
activity is enhanced due to a variety of anti-depressant treatments (Carlezon Jr et al., 2005; 
Gourley et al., 2008; Thome et al., 2000). Anxiety-like behaviours can be modulated by 
changing the function or expression of CREB as studies demonstrated that CREB knock-out 
mice displayed an increase in anxiety-like behaviours (Valverde et al., 2004; Vogt et al., 2014). 
The mechanism of the modulation of anxiety-like behaviours are poorly understood. A report 
by demonstrated that anxiety-like behaviours can be modulated by the 5-HT1A   activation via 
CREB in the hippocampus which promotes neurogenesis and synaptogenesis (Zhang et al., 
2016). A disruption in CREB activity stopped the anxiolytic effect of the 5-HT1aR agonist, 
whereas an increase in CREB activity reversed the anxiogenic effect of the 5-HT1aR antagonist 
(Zhang et al., 2016). There is inadequate understanding of the effects of CBD administration 
on the expression of BDNF and CREB.  
7. Liquid Chromatography- Mass Spectrometry 
Liquid chromatography – tandem mass spectrometry (LC-MS/MS) is a specific and sensitive 
technique used to detect and identify organic and inorganic compounds (Bianchi et al., 2018).  
It is widely used in analytical laboratories as it can be used to provide molecular weight and 
structural information of targeted analytes, and simultaneously determine endogenous 
compounds (Kind & Fiehn, 2010). Mass spectrometers work by converting the analyte 
molecules into an ionized state (Pitt, 2009). Electrospray ionization (ESI) is a soft ionization 
technique that produces ions suitable for mass analysis of biological molecules (Bianchi et al., 
2018). Heated electrospray ionization (H-ESI) is a modification of ESI whereby the ionization 
efficiency of analytes is augmented by the increasing the heating vapourizer temperature to 
quickly evaporate droplets (Kourtchev et al., 2020). The liquid samples are pumped through a 
metal capillary maintained at 3 to 5 kV and nebulized at the tip of the capillary to form a fine 
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spray of charged droplets (Pitt, 2009). The triple quadrapole mass spectrometer is comprised 
of a collision cell between two quadrapole mass analysers (Figure 12) (Pitt, 2009). Each mass 
quadrapole analyser contains a set of four parallel metal rods (Pitt, 2009). The transmission of 
a narrow band of m/z along the axis of the rods is a result of constant and varying voltages 
(Pitt, 2009). Collision induced dissociation (CID) is a process where ions can be induced to 
undergo fragmentation by collision with an inert gas (Pitt, 2009). There are various operational 
modes of the triple quadrapole mass spectrometers such as product scan, precursor scan and 
multiple reaction monitoring (MRM) (Pitt, 2009). The triple quadrapole analysers are widely 
used in LC-MS applications due to the ease of scanning and the good quality quantitative data 
obtained (Bianchi et al., 2018).  
 
Figure 12: Schematic representation of the LC-MS/MS process (adapted from (Mertens, 
2016) 
Key: LC: Liquid Chromatography; MS/MS: Mass Spectrometer/Mass Spectrometer; Q1: 
Quadrapole 1; Q2: Collision Cell; Q3: Quadrapole 3. 
8. Polymerase Chain Reaction (PCR) 
Polymerase chain reaction is a technique used to amplify specific DNA fragments a billionfold 
(Hindson et al., 2013; Pierce, 2012). PCR is based on replication catalysed DNA polymerase 
to synthesis a new complementary strand of DNA to the original template (Y. Kim, Flynn, 
Donoff, Wong, & Todd, 2002). PCR uses a temperature modulation process consisting of 
heating and cooling cycles, called thermal cycling. PCR usually consists of three steps: 
denaturation, annealing and elongation, which is performed in repeated cycles as shown in 
Figure 13 (Chen et al., 2019). During denaturation, the DNA solution is heated at 94°C - 96°C 
for 1 – 2 minutes to separate double-stranded DNA complexes and produce single strands 
(Chen et al., 2019). The strands are then rapidly cooled to between 30°C - 65°C to allow single-
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stranded primers to anneal to their complementary sequences (Chen et al., 2019). In the final 
step of elongation, the solution is heated to 72°C and DNA polymerase synthesizes new DNA 
strands by allowing the primers to extend into the new complementary strands (Chen et al., 
2019). After one cycle of PCR, there are two double-stranded DNA molecules produced for 
each original molecule of target DNA, doubling the amount of target DNA in each cycle 
(Pierce, 2012). As PCR progresses, the cycles are repeated, and the amount of target DNA are 
exponentially increased (Pierce, 2012).  
 
Figure 13: The three steps of PCR and exponential amplification of the target DNA 
(adapted from (Pierce, 2012) 
Key: Blue bars: target DNA; Green bars: New DNA; Green blocks: Primers 
 
9. Aims and objectives: 
Aim: to investigate the potential use of CBD in the treatment of anxiety by assessing NT levels 
and molecular changes in BDNF and CREB signalling in a healthy rodent model. 
Objectives: 
1. To develop an LC-MS/MS method for the simultaneous detection of dopamine, GABA, 
serotonin, norepinephrine and glutamate. 
2. To determine the pharmacokinetic parameters (pK) of CBD in a healthy rodent brain. 
3.  To investigate the neurotransmitter changes in response to CBD administration. 
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4. To determine the expression levels of BDNF and CREB in response to CBD 
administration. 
10. Thesis outline 
Chapter 2 presents the results of the research study. 
Chapter 3 presents the general discussion and conclusion.  
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Cannabidiol (CBD), a non-psychoactive component of the Cannabis sativa plant, has gained 
pharmacological interest due to its therapeutic potential in the treatment of neurological 
disorders. Anxiety-related disorders are some of the most prevalent mental health disorders. 
However, the current pharmacological anxiety treatments display shortcomings in drug 
efficacy, side effects and therapeutic action. Studies have reported the use of CBD in the 
management of anxiety-related disorders however its exact neurological action remains 
unknown, making it crucial to understand the effect of CBD on neurotransmitter levels and the 
expression of CREB/BDNF expression in the brain. Twenty-seven male Sprague-Dawley rats 
received an acute treatment of 10 mg/kg body weight of CBD via intraperitoneal injection. The 
pharmacokinetics of CBD, neurotransmitter concentrations, and CREB/BDNF expression in 
the brain were measured in the brain over 24 hours via LC-MS and qPCR respectively. CBD 
reached a Cmax of 152.801 ± 1.541 ng/ml at 1-hour post drug administration. The results showed 
that GABA and glutamate were significantly decreased between 4 hours and 24 hours in 
response to CBD administration with norepinephrine diminishing over the 24 hours period. 
The concentration of serotonin peaked at 1-hour post drug administration, whereas dopamine 
levels increased at 30 minutes and 2 hours. CBD significantly increased BDNF at 2 hours 
following administration, and CREB expression was upregulated when compared to the control 
over the 24 hours. This study contributes to the understanding of the pharmacodynamic effects 
of CBD in the brain by demonstrating its effects on target neurotransmitters and important 
expression factors.  
Significance statement 
The legalization of cannabis products in many regions of the world has seen it receive interest 
in the treatment of mental health disease, neurodegenerative disorders and inflammatory 
diseases. Despite showing clinical efficacy in the management of these disorders, the exact 
mechanisms remain to be fully elucidated. Therefore assessing the pharmacodynamic effects 
of CBD in the brain, by evaluating neurotransmitter changes, and its effect on the expression 
of CREB/BDNF will contribute to increasing the knowledge of the neurological action of CBD 
and can assist clinicians in better understanding its effects allowing them to make more 




1. Introduction  
Anxiety disorders are the most prevailing neuropsychiatric disorders and are concomitant with 
a high burden of disease and substantial health care expenses (Bandelow & Michaelis, 2015). 
Patients with anxiety experience an immense burden on societal resources which contribute to 
the pathogenesis of depression and the development of physical illnesses (Kariuki-Nyuthe & 
Stein, 2015). Anxiety-related disorders are associated with a decreased sense of well-being, 
elevated rates of unemployment and relationship breakdown, and increased suicide risk (Stein 
& Sareen, 2015). Anxiety can be conceptualized by the inappropriate emotional responses to 
potential threats or danger and sub-divided based on the type of anxious stimuli (A Rabinak & 
Phan, 2014; Sartori & Singewald, 2019). Anxiety disorders include Generalized Anxiety 
Disorder (GAD), Panic Disorder (PD), Social Anxiety Disorder (SAD), and specific phobias 
(Kogan et al., 2016; Reed et al., 2019). Social anxiety disorder is the most prevalent anxiety 
disorders where people display fear and avoidance of the scrutiny of others (Stein & Stein, 
2008). The onset of social anxiety disorder by age 11 is 50 % prevalence and reaches up to 80 
% prevalence in 20-year olds (Stein & Stein, 2008). Generalized Anxiety Disorder is one of 
the most common and most impairing anxiety conditions, it is defined by an insistent, multi-
focal chronic worry (Stein & Sareen, 2015). Neurological disorders, such as depression and 
anxiety, are a result of impairments in the modulation of neural circuits in many limbic brain 
regions including the amygdala, bed nucleus of the stria terminalis, hippocampus and thalamus 
(Nuss, 2015).  
Dysfunction in various brain areas viz. the amygdala, hippocampus and the prefrontal cortex 
are responsible for anxiety (Bremner, 2002). The etiology of anxiety disorders also involve 
dysfunction of the mono-aminergic neurotransmitter systems such as the norepinephrine (NE), 
dopamine (DA) and serotonin (5-HT) systems and their receptors (Liu, Zhao, & Guo, 2018). 
These neurotransmitter systems have a mutual interaction in the central nervous system, 
modulating human emotion, anxiety and depression (Quesseveur, M Gardier, & P Guiard, 
2013). The serotoninergic system consists of differentially expressed multiple 5-HT receptors 
which produce both anxiolytic and anxiogenic effects via differential neurotransmission 
(Albert, Vahid-Ansari, & Luckhart, 2014). Anxiety may be caused by the suppression of the 
postsynaptic 5-HT receptors, upregulation of 5-HT1A receptors or a decreased 5-HT 
neurotransmission (Albert et al., 2014). The 5-HT1A receptor plays an important role in 
mediating the effects of 5-HT in the etiology and treatment of anxiety (Akimova, 
Lanzenberger, & Kasper, 2009). The hyperactivity of norepinephrine in the central nervous 
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system is proposed to cause anxiety symptoms (Liu et al., 2018). During stress conditions, the 
activation of the NE energy pathway by corticotrophin-releasing factors, releases NE, inducing 
anxiety symptoms (Liu et al., 2018). Studies have also demonstrated DAergic 
neurotransmission in the processing of anxiety (Vicario, Rafal, Martino, & Avenanti, 2017). 
The emergence of fear and anxiety occurs due to a deficiency in DA receptor function (Liu et 
al., 2018). The DA receptors are inhibited in the prefrontal cortex and the amygdala which 
induces the hyperexcitability of the amygdala (Liu et al., 2018). Patients with anxiety disorders 
are reported to have decreased DA transporter density and D2 receptor binding in the striatum 
(Shin & Liberzon, 2010).  
A combination of pharmacotherapy and psychotherapy is used to treat anxiety disorders 
(Bandelow, 2017). Traditional pharmacotherapeutic approaches target specific neurochemical 
imbalances (Sartori & Singewald, 2019). Monoaminergic neurotransmitter systems such as the 
endocannabinoid, GABA-ergic and glutamatergic systems, as well as their receptors are 
responsible for the regulation of anxiety and fear ((Bandelow, Michaelis, & Wedekind, 2017); 
Maron et al., 2018).  Recent pharmacological anxiolytic treatments include selective serotonin 
(5-HT) reuptake inhibitors (SSRIs), benzodiazepines, selective noradrenalin reuptake 
inhibitors (SNRIs) such monoamine oxidase inhibitors, tricyclic antidepressant drugs, and 
partial 5-hydroxytryptamines (5-HT) 1A receptor agonists (Bandelow et al., 2017). SSRIs are 
reported to be the first-line pharmacotherapeutics due to their favourable benefit/risk ratio 
(Bandelow et al., 2017). Acute administration of SSRIs stimulates the presynaptic 5-HT 
receptors, which subsequently yield anxiogenic-like effects (Liu et al., 2018) The current 
pharmacological anxiolytic treatments are suboptimal with regards to efficiency and 
tolerability of the drug, abiding adverse side effects, expensive drug development and a reduced 
rate of successful drug discovery (Guina & Merrill, 2018; Sartori & Singewald, 2019). These 
shortcomings highlight the need for improved and novel pharmacological treatments for 
anxiety disorders (Sartori & Singewald, 2019). 
Cannabidiol (CBD), a non-psychoactive phytocannabinoid, is a constituent of the Cannabis 
sativa plant, which has become increasingly popular as a proposed treatment for a spectrum of 
neuropsychiatric disorders (Blessing, Steenkamp, Manzanares, & Marmar, 2015). Existing 
preclinical evidence displays the extensive range of action of CBD: anxiolytic (Campos, 
Moreira, Gomes, Del Bel, & Guimaraes, 2012; Izzo, Borrelli, Capasso, Di Marzo, & 
Mechoulam, 2009) reduction of conditioned fear expression (Resstel, Joca, Moreira, Corrêa, 
& Guimarães, 2006), augmentation of fear extinction (Bitencourt, Pamplona, & Takahashi, 
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2008), the prevention of the abiding anxiogenic effects from stress (Campos, Ferreira, & 
Guimarães, 2012) and the reconsolidation blockade of adverse memories (Stern, Gazarini, 
Takahashi, Guimarães, & Bertoglio, 2012). The anxiolytic action of cannabidiol is mediated 
by the Cannabinoid-1-receptors (CB1R), 5-HT1A receptors and the TRPV1 receptors (Blessing 
et al., 2015).  The complex activation of CB1R produces anxiolytic effects relevant to multiple 
anxiety disorder symptoms (McLaughlin, Hill, & Gorzalka, 2014; Ruehle, Rey, Remmers, & 
Lutz, 2012). CB1R activation in different brain loci may augment or reduce fear expression, 
enhance fear extinction and prevent the reconsolidation of fear (Llorente-Berzal et al., 2015). 
CBD functions as an indirect agonist of CB1R by either decreasing its constitutional activity, 
or increasing the endocannabinoid, anandamide, through the inhibition of fatty acid amide 
hydrolase (FAAH) (McPartland, Duncan, Di Marzo, & Pertwee, 2015). The 5-HT1A receptor 
is an anxiolytic target which prevents the negative effects of stress and increases fear extinction 
(Saito et al., 2013; Zhou et al., 2014). The anxiolytic effects of 5-HT1A have complex 
mechanisms that vary between brain region and pre-versus postsynaptic locus (Celada, 
Bortolozzi, & Artigas, 2013). In vitro studies suggest that CBD acts as a direct 5-HT1AR 
agonist, whilst in vivo studies are more consistent with CBD acting as an allosteric modulator, 
or facilitator of 5-HT1A signalling (Rock et al., 2012; Russo, Burnett, Hall, & Parker, 2005). 
Brain derived neurotrophic factor (BDNF) is a neurotrophin implicated in anxiety and 
depression. BDNF exhibits a neuroprotective effect and has decreased levels in patients with 
anxiety. Studies have shown that anti-depressant effects induced by CBD are associated with 
an upregulation in BDNF levels. The nuclear transcription factor, cyclic AMP response 
element binding protein (CREB) is crucial in memory and learning (Bourtchuladze et al., 1994; 
Josselyn et al., 2001), drug addiction (Pliakas et al., 2001), and anti-depressant effects 
implicated in mood disorders (Gourley et al., 2008; Nestler et al., 2002) The expression and 
function of CREB in the hippocampus, amygdala, hypothalamus and thalamus is increased as 
a result of anti-depressant and anti-anxiety therapeutics such as SSRIs (Carlezon Jr, Duman, & 
Nestler, 2005; Pandey, Zhang, Roy, & Xu, 2005; T. L. Wallace, Stellitano, Neve, & Duman, 
2004). SSRIs induces anxiolytic effects via the 5-HT1A receptors, which elevates CREB 
expression in the hippocampus (Zhang et al., 2010) Despite the demonstrated clinical efficacy 
and increasing knowledge surrounding the use  of CBD as an anxiolytic treatment, the effects 
of CBD on neurotransmitter systems contributing to the treatment of anxiety, BDNF and CREB 
expression remain unknown. 
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Therefore, this study aimed to evaluate the pharmacodynamic effects of acutely administered 
cannabidiol (10 mg/kg body weight) by assessing brain neurotransmitter levels and the 
expression of BDNF and CREB in the healthy rodent brain in order to better understand its role 
in the treatment and management of anxiety-related disorders.  
2. Materials and Methods 
2.1 Experimental subjects   
Twenty-seven male Sprague-Dawley rats (110 – 120 g) were sourced from the University of 
KwaZulu-Natal Biomedical Resource Unit (Westville campus). The animals were collected 
two weeks prior to the experimental procedures to allow for acclimatization. The animals 
were housed in well-ventilated cages, located in temperature and humidity-controlled housing 
units, with a 12-hour/ 12-hour light-dark cycle. Environmental enrichment, in the form of 
shredded paper and plastic tunnels, were added to the cage. The animals were provided with 
commercially pelleted feed and clean water ad libtium. 
2.2 Ethical approval 
The experimental protocols used in this study were approved by the University of KwaZulu-
Natal institutional Animal Research Ethics Committee (approval reference: AREC/010/019M). 
This was in accordance with the regulations of the South African National Legislations for 
animal husbandry, welfare and experimentation using laboratory animals.  
2.3 Experimental design and procedure 
2.3.1. Drug treatment and animal experiments 
The animals were treated with 10 mg/kg body weight of pure cannabidiol (CBD) was extracted 
from the Cannabis sativa plant and its identity confirmed via LC-MS and NMR. The CBD was 
dissolved in a 1:9 mixture of hexane: ultrapure water (Milli-Q water). A volume of 1 ml/ 250g 
body weight was administered via intraperitoneal (i.p.) injection to the animals (Deiana et al., 
2012; Long et al., 2010; Taffe, Creehan, & Vandewater, 2015; Wiley, O'Connell, Tokarz, & 
Wright, 2007). The animals were sacrificed at different time points (Table 1) to determine the 
pharmacokinetics of CBD in the brain, as well as associated neurotransmitter changes at 
different time points. These time intervals were determined based on previous pharmacokinetic 
studies involving CBD following various lengths of exposure (Deiana et al., 2012).  
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Table 1: Acute exposure group and the number of animals to be terminated at the time 
points of euthanasia 
 Time post CBD administration (hours) Total number of animals 
 0 0.25 0.5 1 2 4 6 8 24  
N 3 3 3 3 3 3 3 3 3 27 
 
Experimental animals were euthanized by decapitation, following which the brain tissues were 
surgically removed, cooled on ice for 15 minutes, and subsequently frozen using liquid nitrogen 
vapour. Blood was collected into heparinized tubes and centrifuged at 10 000 rpm for 7 minutes 
to obtain the blood plasma. The brain tissues and plasma samples were stored at -80 °C until 
analysis.  
2.3.2. Liquid chromatography – Mass Spectrometry/ Mass Spectrometry (LC-
MS/MS) analysis  
2.3.2.1 Neurotransmitter analysis 
LC-MS/MS analysis was conducted using a Thermo Scientific Quantis Triple Quadrupole 
Mass Spectrometer (Thermo Scientific, Massachusetts, USA) coupled to a Thermo Scientific 
Vanquish Ultra High-Performance Liquid Chromatography (UHPLC) System (Thermo 
Scientific, Massachusetts, USA). The system was controlled using the Thermo Scientific SII 
Xcalibur 1.3 (version: 3.0.20389) and Thermo Trace finder General (version: 4.1 SP5) software 
packages. Liquid chromatographic separation was achieved using the Poroshell 120 EC-C18 
(50 mm x 4.6 mm, 2.7 µm) column (Agilent technologies) to assay serotonin (5-HT), GABA, 
norepinephrine (NE), glutamate (GLU), and dopamine (DA). The column compartment 
temperature was maintained at 25 °C.  Mobile phase A was ultrapure water (0.1 % Formic 
Acid) and mobile phase B was methanol (0.1 % Formic acid). A flow rate of 0.800 ml/min was 
utilized, with a sample injection volume of 20 µl. The Heated Electrospray Ionizer (H-ESI) 
mass spectrometer was operated in the positive mode. The source parameter MS settings 
included: Spray voltage, 4809 V; Sheath gas, 50 Arbitrary units; Auxiliary gas, 15 Arbitrary 
units; Sweep gas, 1.2 Arbitrary units; vapourizer temperature, 400 °C; and ion transfer tube 
temperature, 325 °C. The MS scan parameters were as following: cycle time, 0.6 seconds; Q1 
and Q3 resolution, 0.7; collision induced dissociation (CID) gas pressure, 1.5 mTorr; and 
chromatographic peak width, 12 seconds. The mass transitions monitored via selected reaction 
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monitoring (SRM) and ion optic parameters are defined in Table 2. The gradient profile used 
for the elution of neurotransmitters is  -1.00 min(pre-injection equilibration): 15 % B; 0.00 
mins: 15 % B; 1.00 min: 70 % B; 1.10 mins: 95 % B; 5.50 mins: 95 % B; 5.60 mins:15% B; 
5.60 – 8 mins: 15 % B; with a total run time of 8 mins. 
Table 2:Selected Reaction Monitoring (SRM) and Ion optic parameters of 




















137 Quantifier 14.55 78 9.473 
90.946 Qualifier 27.51 78 9.473 
118.929 Qualifier 15 78 9.473 
GABA  
104.05 
87 Quantifier 13.41 30 9.473 
46 Qualifier 55 30 9.473 
85.875 Qualifier 15 30 9.473 
Glutamate 148.05 84.071 Quantifier 18.98 30 9.473 






152.054 Quantifier 10.23 79 9.473 
107.018 Qualifier 23.99 79 9.473 




159.982 Quantifier 10.23 30 9.473 
114.929 Qualifier 46.7 30 9.473 






164.02 Quantifier 10.23 192 9.473 
78.557 Qualifier 34.57 192 9.473 







193.083 Quantifier 32.56 95 13.115 
259.137 Qualifier 27.17 95 13.115 
135.173 Qualifier 29.64 95 13.115 
235.167 Qualifier 28.16 95 13.115 
123.071 Qualifier 48.37 95 13.115 
 
2.3.2.2. Cannabidiol analysis 
The liquid chromatographic separation of CBD was achieved using the Biphenyl Pinnacle DB 
column (50 mm x 2.1 mm, 5 µm) (Restek, USA). The column compartment temperature, 
mobile phases and injection volume, and MS source and scan parameters are according to 
section 2.3.2.1. The gradient profile for the elution of CBD was -1.00 min: 50 % B; 0.00 mins: 
50 % B; 1.50-5.00 mins: 98 % B, 5.10 mins; 50 % B, 5.10-8 mins: 50 % B; with a flow rate of 
0.300 ml/min and a total run time of 8 mins.  
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2.3.3. Sample preparation of brain tissue 
Frozen brain samples were swiftly dissected on an ice bath, into hemispheres, using surgical 
blades. One hemisphere of the brain was subsequently homogenized using the OMNI tissue 
homogenizer (OMNI international, Kennesaw Georgia, USA). The brain tissue homogenates 
were diluted with a 1:1 v/v of MilliQ water.  100 µl of brain tissue homogenate was added to 
850 µl methanol spiked with 50 µl of internal standard (10 µg/ml). The solutions were 
centrifuged at 10 000 rpm for 10 minutes at 4°C. The supernatants were carefully transferred 
to the conditioned Solid Phase Extraction (SPE) Discovery® DSC18-100mg cartridges 
(Merck, Gauteng, South Africa) for extraction.  
2.3.4. Solid Phase Extraction  
A SPE diaphragm vacuum pump manifold with Discovery® DSC18-100mg 1 ml cartridge 
tubes (Merck, Gauteng, South Africa) were utilized. Prior to the elution of samples, the C18 
cartridges were conditioned with 1000 µl of 100% methanol under vacuum pressure. The 
supernatants were eluted at a rate of 1 ml/minute under vacuum pressure and the flow through 
collected for LC-MS/MS analysis. 400 µl of the collected eluent samples were dried in a 
nitrogen evaporator, ZipVap (Glass-Col, Indiana, USA) at 55°C for 15 – 17 minutes at a 
constant flow of nitrogen gas at 2 bars. The samples were then reconstituted in 400 µl of 
ultrapure water and vortexed for 30 seconds.   
2.3.5. Preparation of neurotransmitter and internal standards stock solutions  
A 1 mg/ml multi-mix stock solution of neurotransmitters (DA, GABA, GLU, NE and 5-HT) 
and their respective internal standards was prepared by accurately weighing 1 mg of each 
compound and dissolving it in 100 µl water: 900 µl methanol. The multi mix solution of 
neurotransmitters and internal standards was then diluted with methanol to 10 µg/ml and 1 
µg/ml working solutions  
2.3.6. Preparation of calibration standards for the calibration curve 
The samples for the calibration curve were prepared by spiking the blank solution (methanol) 
with the appropriate volume of the multi-mix neurotransmitter stock solution. Yielding final 
concentrations of 50, 150, 250, 500, 750, 1000 ng/ml which were used to construct a calibration 
curve. The neurotransmitter multi-mix was spiked with internal standard at a concentration of 
500 ng/ml in each calibration sample. Cannabidiol (CBD) calibration standards were prepared 
in solution at final yielding concentrations of 0.98, 1.95, 3.9, 7.8, 15.625, 31.25, 62.5, 125, 250 
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and 500 ng/ml. The CBD samples in solution were prepared by spiking methanol with the 
appropriate volume of CBD.  
2.4. Gene expression analysis 
2.4.1. RNA extraction 
Brain tissue homogenates were centrifuged at 10 000 x g at 4°C for 10 minutes. The 
supernatants were transferred into autoclaved micro-centrifuge tubes containing 500 µl of 
Qiazol reagent (Qiagen, Hilden, Germany) and stored at -80°C until extraction. RNA 
extractions were performed by adding 100 µl of chloroform to the tissues stored in Qiazol. The 
solutions were then vortexed for 15 seconds and incubated at room temperature for 2 – 3 
minutes. The tubes containing the organic phase in Qiazol and chloroform were centrifuged at 
12 000 x g for 12 minutes at 4 °C, and 250 µl of the aqueous phase, containing crude RNA, 
was transferred to a micro-centrifuge tube. 250 µl of isopropanol was added to each aqueous 
sample and mixed by flicking. The samples were incubated overnight at -80 °C. The samples 
with isopropanol were centrifuged at 12 000 x g for 20 minutes at 4 °C. The supernatant was 
discarded and 500 µl of 75% cold ethanol was added to release the pellet. The pellet in ethanol 
was centrifuged (7 400 xg, 15 minutes, 4°C). The ethanol was discarded, and the pellet allowed 
to air dry. The pellets were resuspended in 15 µl of nuclease-free water and incubated at room 
temperature for 2-3 minutes. The samples were stored at -80 °C and the Nanodrop 2000 
spectrophotometer (Thermo-Fisher Scientific, Massachusetts, USA) was used to quantify 
RNA, which was standardized to 1000 ng/µl and the A260/ A280 absorbance ratio was used to 
assess RNA purity. 
2.4.2. cDNA synthesis  
The RNA templates were reverse transcribed into cDNA using Maxima H Minus First Strand 
cDNA Synthesis Kit (Thermo-Fisher Scientific, California, USA). The master mix (excluding 
template RNA) consisted of 0,25 µl Oligo (dT)18 primer (25 p mol), 1 µl 10 mM dNTP mix 
and 12,75 µl nuclease-free water. 1000 ng/µl template RNA was added and gently mixed and 
incubated for 5 minutes at 65 °C. The samples were stored on ice. The second master mix 
consisted of 4 µl of 5x RT Buffer and 1 µl Maxima H Minus enzyme mix.  This master mix 
was added to all samples and incubated in the Applied Biosystems Viia real time PCR system 
thermo-cycler (Thermo-Fisher Scientific, USA) (10 minutes at 25°C, then 15 minutes at 50 
°C). The reaction was terminated by incubating at 85 °C for 5 minutes. 60 µl of nuclease-free 
water was added to the samples and stored (-80 °C) until qPCR processing. 
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2.4.3. qPCR analysis 
The primers used for qPCR analysis were BDNF: Sense: 5'-
GAATTCATGACCATCCTTTTCCTTACTATG-3', Anti-sense: 5'-
AAGCTTTCTTCCCCTTTTAATGGTCAG-3'; and CREB Sense: 5'-
CCAAACTAGCAGTGGGCAGTATATT-3', Anti-sense: 5'-
GGTACCATTGTTAGCCAGCTGTATT-3' were used at a final concentration of 25 µM. The 
PowerUp™ SYBR™ Green Master Mix (Thermo-Fisher Scientific, California, USA) 
contained 5 µl SYBR Green, 2 µl nuclease-free water, 1 µl sense primer (25 µM), and 1 µl 
anti-sense primer (25 µM). The master mix was added to the well, along with 1 µl of 1000 ng 
cDNA. The plate was centrifuged at 1000 xg at 24 °C for 1 minute. The mRNA amplification 
of BDNF and CREB were performed on the Applied Biosystems Viia 7 Real-Time PCR system 
(Thermo-Fisher Scientific, California, USA). The thermal cycling profile for PCR for BDNF 
and CREB was as follows: initial denaturation (1 cycle) at 95 °C for 8 minutes, PCR (40 cycles) 
consisting of denaturation  at 95 °C for 15 seconds, annealing  at 60 °C for 40 seconds, and 
extension at 72 °C for 30 seconds . The samples were run as triplicates. The housekeeping gene 
GAPDH (Sense: 5’-GGCACAGTCAAGGCTGAGAATG-3’,Anti-Sense: 5’–
ATGGTGGTGAAGACGCCAGTA-3’) was used to normalized the variances in gene 
expressions and the data was presented as fold change (2^CCT) relative to the control (Livak 
& Schmittgen, 2001). 
2.5.  Materials 
The neurotransmitter standards were purchased from Sigma-Aldrich (St. Louis, USA): (-)-
Norepinephrine, Serotonin, L-Glutamic acid monosodium salt monohydrate, γ-Aminobutyric 
acid (GABA), and Dopamine hydrochloride (Steinheim, Germany). The internal 
neurotransmitter standard Serotonin D4 hydrochloride was obtained from ClearSynth
® 
Research Chemicals Inc (Ontario, Canada). Hexane was obtained from Merck (Darmstadt, 
Germany) and formic acid (Merck, Gauteng, South Africa). LC-MS grade Methanol was 
purchased from Honeywell (Steinheim, Germany). Milli-Q water was purified using the Milli-
Q® water purifying system (Merck Millipore, Burlington, MA).  
 
2.6 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism v8.4.3  (GraphPad Software, San 
Diego, California USA, www.graphpad.com). GraphPad Prism Software was used to analyse 
data using the unpaired multiple t-test with statistical significance determined using the Holm-
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Sidak t-test method (alpha = 0.05). Results were expressed as mean ± standard deviation (SD). 
Level of significance (p) was established at a p < 0.05 The pharmacokinetic (pK) parameters 
were calculated using Stata/IC 15.0 (StataCorp LLC, Texas, USA, www.stata.com). 
3. Results 
Following i.p. administration of 10 mg/kg b.w. CBD to Sprague-Dawley rats, the concentration 
of CBD, and neurotransmitters (DA, 5-HT, NE, GLU and GABA) were measured using LC-
MS/MS analysis. The results of the drug concentration, neurotransmitter levels and molecular 
changes in the brain were analysed using unpaired multiple t-tests to determine the statistical 
significance between the time intervals post administration compared to the control. 
(A) the concentration-time curve of CBD over time following i.p. administration (B) GABA 
brain concentrations following acute i.p. CBD administration. (C) Glutamate brain 
concentrations over 24 hours post i.p. CBD administration (D) DA brain concentrations 
following i.p. CBD administration (E) the effect of CBD on brain Serotonin concentration over 
24 hours (F) Brain NE concentration against time post CBD administration. Unpaired multiple 
t-tests were conducted using the Holm-Sidak t-test method. * P < 0.05, ** P < 0.01, *** P < 
Figure 14: Mean brain concentration-time profile of cannabidiol and neurotransmitters following i.p. 
administration of CBD 
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0.001, **** P < 0.0001 compared to the control, where T = 0 hours represented the control 
in all graphs. (data presented as mean ± SD, n = 3). 
In Figure 14A, CBD was first detected in the brain at (0.25 hours) post-administration (5.87 ± 
2.441 ng/ml, P < 0.05). The Tmax of CBD (the time at which the maximum concentration was 
reached) was at 1-hour post administration with a Cmax of 152.801 ± 1.541 ng/ml (P < 0.0001) 
was reached (Table 3). After 1 hour, the concentration of CBD in the brain steadily decreased 
until it reached a concentration of 6.904 ± 2.174 ng/ml (P < 0.01) at 24 hours post-
administration. The CBD concentration in brain is statistically different among the groups 
where P < 0.05 for all time points against the control.  
The effect of cannabidiol on the level of neurotransmitters in the brain is depicted in Figure 14. 
GABA (14B) is downregulated, with the lowest concentration of 891.98 ± 58.71 ng/ml at 4 
hours (P < 0.05). The levels of GABA in the brain were then elevated from 6 hours (944.35 ± 
146.65 ng/ml, P < 0.05) to 24 hours (1144.49 ± 24.99 ng/ml, P < 0.05). Glutamate (14C) levels 
were significantly decreased from the control (1297.25 ± 120.04 ng/ml, P > 0.05) to 4 hours 
(659.96 ± 47.91 ng/ml, P < 0.001), 6 hours (771.10 ± 37.80 ng/ml, P < 0.01) and 8 hours 
(822.72 ± 47.54 ng/ml). Glutamate experienced a decline from 1 hour to 4 hours post CBD 
administration, and thereafter displayed a rise in levels from 6 hours onwards. The Cmax of 
dopamine (14D) in the brain was 41.34 ± 3.82 ng/ml at 0.5 hours, followed by a decrease that 
occurred at 1 hour (Tmax of CBD) with a concentration of 28.797 ± 0.36 ng/ml. The levels of 
dopamine spiked at 2 hours (35.39 ± 2.57 ng/ml), and thereafter diminished at 4 hours (28.10 
± 2.90 ng/ml) and remained at similar levels until 24 hours (27.45 ± 1.34 ng/ml) post dosing. 
The Cmax of serotonin (14E) (22.746 ± 1.40 ng/ml) was achieved at 1 hour, which corresponds 
to the Tmax of CBD. Serotonin brain concentration over time did not have a significant 
difference against the control. Norepinephrine (14F) was decreased over time from the control 








Table 3: A summary of the pharmacokinetic parameters of CBD following acute i.p. 
administration of 10 mg/kg b.w. CBD 
Cmax (ng/ml) 152.8 
Tmax (hour) 1 
T1/2 (hour) 8.35 
Kel 0.0830 
AUC0-inf (ng min/ml or ng min/g) 605.015 
 
 
Figure 15A displays the fold changes in BDNF expression in the brain over 24 hours post i.p. 
CBD administration. Figure 15B shows the CREB expression levels in the brain over 24 hours 
post i.p. CBD administration. T = 0 hours is the control. Unpaired multiple t-tests were 
performed to detect differences in BDNF expression (15A) and CREB expression (15B) 
respectively, between the control and time points post CBD administration. * P < 0.05, ** P 
< 0.01, *** P < 0.001, **** P < 0.0001. Data are expressed as mean ± SD (n = 3). 
In figure 15A, CBD (10 mg/kg body weight significantly augmented BDNF at 30 minutes 
(1.637 ± 0.13, P < 0.001) and at 2 hours (29.517 ± 3.21, P < 0.0001). The drastic increase of 
BDNF at 2 hours can be correlated with a high CBD brain concentration (102.82 ng/ml ± 15.44) 
at 2 hours (Figure 14A).  BDNF levels were significantly decreased at 15 minutes (0.810 ± 
0.020, P < 0.0001), 8 hours (0.770 ± 0.142, P < 0.05) and 24 hours post administration (0.387 
Figure 15: The effect of CBD administration on the expression of CREB and BDNF at 
various time intervals. 
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± 0.126, P < 0.001). CREB levels (15B) in the brain were significantly increased at 4 hours 
(1.837 ± 0.025, P < 0.0001), 6 hours (1.373 ± 1.37, P < 0.05), 8 hours (1.413 ± 0.189, P < 0.05) 
and 24 hours (1.930 ± 0.235, P < 0.01) post administration.  
4. Discussion 
The therapeutic use of CBD in the treatment of anxiety has been increasingly studied in both 
preclinical and clinical studies (Bandelow et al., 2017). The primary objective of this study was 
to investigate the neurochemical effects induced by acute exposure of CBD. The mechanism 
of action of CBD in anxiety related disorders was evaluated by assessing the changes in brain 
neurotransmitter concentration, BDNF and CREB expression in male Sprague Dawley rats. 
The Cmax of CBD at 1 hour (Figure 14A) is supported by previous studies (Deiana et al., 2012) 
and (Hložek et al., 2017), who showed that varying routes of CBD administration have a half-
life of 60 – 120 minutes, thereafter experiences a continuous decline towards 24 hours. Based 
on these findings CBD has been shown to attenuate anxiety levels in healthy individuals 2 
hours post-administration (Martin-Santos et al., 2012). 
Cannabidiol acts as an indirect agonist at the CB1R and may inhibit the release of 
neuromodulatory systems such as, 5-HT, NE and DA,  thus reducing its concentration in the 
brain (Rubino et al., 2008). A deficiency of serotonin (5-HT) in the brain is strongly associated 
with negative emotions involved in anxiety disorders and major depressive disorders (Liu et 
al., 2018). The overlap of pharmacological treatment of anxiety and depression, such as SSRIs 
which are 5-HT partial agonists, exert their therapeutic potential by facilitating 5-HT 
neurotransmission and upregulating extracellular 5-HT concentrations (Artigas, 2013; 
Gartside, Umbers, Hajos, & Sharp, 1995). The agonistic action of CBD at the 5-HT1ARs 
causes a suppression in glutamatergic and GABAergic transmission (Russo et al., 2005). A 
study by (De Gregorio et al., 2019) concluded that acute dosing of CBD (0.1 – 1.0 mg/kg) 
reduced the firing rate of 5-HT neurons. However, repeated administration of CBD resulted in 
an increase in 5-HT activity and reduced anxiety-like behaviour through the agonism of 5-
HT1A receptors (De Gregorio et al., 2019; Russo et al., 2005). The reduced concentration of 
serotonin in this study can be attributed to the acute administration of CBD, thus only 
increasing when CBD was at its maximum concentration (Figure 14E). The anxiolytic effects 
of the 5-HT1A receptors are activated during chronic treatment of SSRIs and CBD, whereas 
anxiogenic effects may be produced in response to acute SSRIs and CBD administration (De 
Gregorio et al., 2019; Liu et al., 2018). In a previous study, an acute, single dose of CBD 
produced an increase in 5-HT levels through a 5-HT1A receptor-dependent mechanism in the 
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OBX murine model of depression (Linge et al., 2016). Behavioural and neurochemical studies 
by (Sales, Crestani, Guimarães, & Joca, 2018) suggest that the anti-depressant and anti-anxiety 
like effects of CBD are dependent on the concentration of serotonin.  
CBD acts on molecular targets that correspond to targets of neurological disorder treatments, 
such as benzodiazepines (Bih et al., 2015). The inhibition and activation of the main inhibitory 
neurotransmitter system, GABA, can be facilitated by CBD agonism at the transient receptor 
potential vanilloid type 1 (TRPV1) receptor (Ho, Ward, & Calkins, 2012; Musella et al., 2009). 
Our findings reported a gradual decrease in the GABA levels in healthy rats as the 
concentration of CBD decreased over time (Figure 14B). A study by (Kaplan, Stella, Catterall, 
& Westenbroek, 2017) demonstrated an anti-seizure effect of CBD in mice with Dravet 
syndrome which was associated with an upregulation of GABA neurotransmission. It is 
suggested that CBD may upregulate the neurotransmission of GABA through the antagonist 
action in the basal ganglia, at the G protein-coupled receptor 55 (GPR55) (Kaplan et al., 2017). 
The exact role of GABA remains unclear as an in vivo study reported an increase in GABA 
levels in healthy control patients, and a decrease of GABA in patients with autism spectrum 
disorder 5 hours post CBD administration (Pretzsch et al., 2019). 
A study by (Pretzsch et al., 2019) also presented a decrease in of glutamate in the dorsomedial 
prefrontal cortex in both healthy and autism spectrum disorder individuals, following the 
administration of 600 mg of CBD p.o. The decline of glutamate levels may have been a result 
of inhibition of the activity of the prefrontal glutamatergic neurons by CBD via the 5-HT1A 
receptors (Russo et al., 2005; Santana, Bortolozzi, Serrats, Mengod, & Artigas, 2004). The 
levels of glutamate also decreased as the concentration of CBD in the brain decreased 2 hours 
post administration (Figure 14C). However, a preclinical study by (Linge et al., 2016) showed 
an augmentation of glutamate in OBX mice. The increase of glutamate release was mediated 
by the action of CBD on 5-HT1A receptors (Linge et al., 2016). The anti-seizure properties of 
CBD were investigated by co-administration of CBD with cocaine (Gobira et al., 2015). The 
results of the study by (Gobira et al., 2015) indicated that CBD attenuates glutamate levels in 
the hippocampus via 5-HT1A receptors..  
During stressed conditions, the hyperactivity of norepinephrine (NE), by corticotrophin 
releasing factors, in the CNS can result in the manifestation of anxiety symptoms (Liu et al., 
2018). The NE levels showed no significant changes after CBD administration (Figure 14F), 
thus postulating that CBD has no significant effect on NE in a healthy rodent model.  This is 
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supported by a study by (Sales et al., 2018) which showed that NE levels were reduced by 
DSP-4, a noradrenalin neurotoxin. The effect of CBD on anxiety-related behaviour during the 
forced-swimming test was dependent of the facilitation of 5-HT  levels rather than NE itself 
(Sales et al., 2018). These results were corroborated as a DSP-4 did not inhibit the anti-
depressive effects of CBD (Ross & Stenfors, 2015). There is a mutual interaction between NE 
and 5-HT neurotransmission as the NE mediated activation of the α2- adrenergic receptors can 
prevent the release of 5-HT (Liu et al., 2018; Quesseveur et al., 2013). 5-HT systems can also 
negatively influence NE neurotransmission through the action of 5-HT2A and 5-HT2C systems 
(Hamon & Blier, 2013). The mutual interaction between NE and 5-HT is a possible explanation 
for the results obtained in this study, as there is a high concentration of NE, whilst the 
concentration of 5-HT remains fairly low (Figure 14E and 14F).  
The dopaminergic system, consisting of different dopamine receptors, is crucial in the 
modulation of anxiety in the amygdala (de la Mora, Gallegos-Cari, Arizmendi-García, 
Marcellino, & Fuxe, 2010) . Previous literature mostly reports the effect of CBD on the 
dopamine receptors, D1 and D2, rather than the concentration of dopamine in the brain 
(Seeman, 2016; Shin & Liberzon, 2010). Studies have provided evidence that the activation of 
the dopamine D1 receptor elicits anxiogenic effects, whereas antagonists induce anxiolytic 
effects in models of anxiety (de la Mora et al., 2010; Kupferschmidt, Newman, Boonstra, & 
Erb, 2012; Zarrindast, Sroushi, Bananej, Vousooghi, & Hamidkhaniha, 2011). The dopamine 
D2 receptors are involved in anxiety-like behaviour in the ventral tegmental area (de la Mora 
et al., 2010; de Oliveira et al., 2011). A decrease in dopamine levels can induce anxiety and 
depression-like behaviours (Jaunarajs, George, & Bishop, 2012). An insufficient function of 
DA receptors may result in failure in inhibition from the PFC to the amygdala, promoting 
hyperexcitability of the amygdala which results in the pathogenesis of anxiety (Liu et al., 2018). 
However, elevated levels of  DA are related to an increase in anxiety and depression in patients 
with paraganglinomas (Bonomaully, Khong, Fotriadou, & Tully, 2014). A study by (Seeman, 
2016) reported the partial agonist activity of CBD on dopamine D2 receptors as CBD prevented 
the binding radio-domperidone, contributing to the anti-psychotic effect of CBD. A study by 
(Murillo-Rodríguez, Palomero-Rivero, Millán-Aldaco, Mechoulam, & Drucker-Colín, 2011) 
demonstrated that perfusion of CBD in a sleep deprived rats increased extracellular DA 
concentrations during and after sleep deprivation, as sleep deprivation is associated with 
diminished DA levels. It can be speculated from our results that the anti-anxiety action of CBD 
as a dopamine agonist occurs at 0.5 and 2 hours post CBD administration as the DA levels are 
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increased (Figure 14D). At the 1-hour following drug dosing, there was a sudden decrease of 
DA (Figure 14D) with a concentration of 28.797 ± 0.356 ng/ml, whilst the level of 5-HT 
(Figure 14F) reached its Cmax of 22.746 ± 1.404 ng/ml. This could be explained by the action 
of 5-HT system via 5-HT2A and 5-HT2C receptors which can inhibit the DAergic system and 
induce short-term motor changes (Clausius, Born, & Grunze, 2009; Liu et al., 2018).  
Diminished BDNF levels are associated with stress, anxiety and depression (Castrén & 
Rantamäki, 2010). CBD, as an anti-depressant therapeutic, has been reported to increase BDNF 
levels in the brain (Giacoppo, Pollastro, Grassi, Bramanti, & Mazzon, 2017). Our results show 
a significant 25-fold increase of BDNF level at 2 hours, which could be a result of the high 
CBD concentration between 1 and 2 hours (Figure 15A). This rapid increase in BDNF is 
supported by (Sales et al., 2019) as BDNF levels in the prefrontal cortex and hippocampus, 
were increased 30 minutes following acute CBD administration (10 mg/kg). The augmentation 
of BDNF in neurodegenerative rodent models is also presented by (Mori et al., 2017) as acute 
CBD treatment increased BDNF levels in the hippocampus. The mechanism of action of CBD 
causing the upregulation in BDNF mRNA levels is unknown, however it is suggested to be a 
result of CBD demonstrating agonism at 5-HT1A receptors (Jiang et al., 2016). The activity of 
CREB in the hippocampus is upregulated in response to anti-anxiety and anti-depressant 
therapies (Carlezon Jr et al., 2005). The mRNA levels of CREB are upregulated post CBD 
administration when compared to the control (Figure 15B). At 1 hour following the 
administration of CBD, 5-HT reached the highest concentration and the expression of CREB 
increased from the control. This is supported by an increase in CREB expression in response 
to anti-depressants, such as SSRIs. The modulation of CREB expression can affect anxiety-
like behaviour as the anxiolytic effect of the 5-HT1A receptor agonist, such as CBD, is 
inhibited by a decrease in CREB activity (Zhang et al., 2016). The agonistic action of SSRIs 
and CBD at 5-HT1A receptors upregulates the phosphorylation of CREB in the hippocampus, 
which results in anti-anxiety behaviour by promoting neurogenesis and synaptogenesis (D. L. 
Wallace et al., 2009; Zhang et al., 2016; Zhang et al., 2010). 
5. Conclusion  
This study demonstrates the pharmacokinetic properties and pharmacodynamic effects of CBD 
in a healthy rodent brain. The findings show that CBD significantly alters the glutamatergic 
and GABAergic neurotransmitter systems in the brain while also significantly increasing 
BDNF expression. The findings of this study are important in not only improving the 
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understanding of the anxiolytic mechanisms of action of CBD but also by contributing to our 
currently limited knowledge on the neurological effects of CBD.  
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Chapter 3 – General discussion and Conclusion 
 
The anti-anxiety properties of CBD have been reported in many clinical and preclinical studies 
(Bandelow, Michaelis, & Wedekind, 2017). Since the legalization of Cannabis in many 
countries, CBD is receiving more attention for its medical properties and as an alternative 
treatment for many ailments, including neurological disorders. The pharmacological profile of 
the psychoactive cannabinoid, THC has been extensively studied, whilst the mechanism of 
CBD is not fully understood (Morales, Hurst, & Reggio, 2017). This study examined the 
pharmacodynamic properties of CBD following acute i.p. administration by evaluating the 
brain concentration of neurotransmitters and BDNF/CREB mRNA expression in a healthy 
rodent model. Our findings show that CBD reached its Cmax at 1-hour post drug administration 
which is consistent with literature as (Deiana et al., 2012) and (Hložek et al., 2017) reported 
the Tmax to be between 1 – 2 hours. A low dose, such as 10 mg/kg used in this study, CBD has 
been reported to induce anxiolytic effects in neurobehavioural studies. This mechanism of 
action can be explained by the agonism of CBD on serotonin 5-HT1A receptors (Campos, 
Ferreira, & Guimarães, 2012; Lee, Bertoglio, Guimarães, & Stevenson, 2017; Russo, Burnett, 
Hall, & Parker, 2005). The anti-anxiety and anti-depressant-like effects of CBD are associated 
with increased BDNF levels, which are usually reduced in anxiety and depression (Castrén & 
Rantamäki, 2010; Sales et al., 2019). The significant 25-fold increase of BDNF found in this 
study, 2 hours post CBD administration is indicative of the rapid effect of CBD on BDNF 
signalling. This increase in BDNF enhances neurogenesis, neuroplasticity and synaptic 
transmission through the activation of the TrKB-mTOR signalling pathway, contributing to the 
sustained anxiolytic effects of CBD (Autry & Monteggia, 2012; Palomares-Castillo et al., 
2012; Sales et al., 2019). The results of this study found an increase in CREB expression 
following acute CBD exposure (Figure 15B). The elevated levels of CREB are known to 
promote synaptogenesis and neurogenesis in response to CBD agonism at 5-HT1A receptors 
(Zhang et al., 2016), while the upregulation of hippocampal CREB expression results in anti-
anxiety effects (Zhang et al., 2016).  
This study demonstrated an increase in 5-HT levels 1-hour post CBD, thereafter, declining over 
time. This could be explained by the anxiolytic effects of CBD being mediated by 5-HT during 
chronic drug exposure  (De Gregorio et al., 2019). Acute treatment of CBD reacts similarly to 
SSRIs, by attenuating 5-HT neuron firing which decreases 5-HT levels as reported in our study 
(Figure 14E), whereas chronic treatment increases 5-HT transmission via desensitization of 5-
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HT1A receptors (De Gregorio et al., 2019; Russo et al., 2005). Norepinephrine is not 
significantly implicated during acute CBD administration, which is also seen in our study 
(Figure 14F)  (Sales, Crestani, Guimarães, & Joca, 2018). 5-HT has been reported to adversely 
affect NE transmission via the 5-HT receptors (Hamon & Blier, 2013). Modifications in 
dopaminergic systems that are responsible for anti-anxiety effects may be mediated by 
increases or decreases in 5-HT and NE signalling (Liu, Zhao, & Guo, 2018). Since diminished  
DA levels are related to anxiety-like behaviour, the increase in DA concentrations at 0.5 hours 
and 2 hours following drug exposure (Figure 14D) suggests that CBD exhibits anxiolytic 
effects by partial agonist action at dopamine D2 receptors and could be extremely beneficial in 
the treatment of anxiety (Seeman, 2016). The primary inhibitory, GABA, and excitatory, 
glutamate, neurotransmitters were significantly reduced from 4 hour following CBD exposure 
(Figure 14B and 14C). The decline in GABA is supported by a decrease in GABA seen in 
autism spectrum disorder (ASD) patients (Pretzsch et al., 2019), whereas an increase in GABA  
promotes anti-seizure affects observed in a Dravet syndrome murine model (Kaplan, Stella, 
Catterall, & Westenbroek, 2017). There are opposing theories regarding the mechanisms of 
action of CBD on GABA sand need to be supplemented with further research. Reports show 
that CBD has contradicting effects on glutamate as reduced levels are reported in ASD patients 
(Pretzsch et al., 2019) and elevated levels in a murine model after CBD p.o. (Linge et al., 2016). 
Glutamate attenuations and elevations are mediated via the 5-HT1A receptors as CBD either 
inhibits or activates the glutamatergic neurons (Gobira et al., 2015; Linge et al., 2016; Russo 
et al., 2005).  
The pharmacological action of CBD is dependent on many mechanisms of action, such as the 
mediation of the 5-HT1A receptors. However, from this study, the implications of other 
neurotransmitter systems have been highlighted. Further pre-clinical studies are required to 
investigate the pathways and receptors involved in the anxiolytic effects of CBD on 
neurotransmission and molecular expression. The acute administration of CBD, without the 
addition of anxiety behavioural models remains a limitation of this study. Future studies into 
the mechanism of action of CBD in the brain should consider the: (1) acute and chronic dosing 
of CBD at varying low-dose concentrations; (2) behavioural tests in anxiety models, such as 
elevated-T-maze, open field test, elevated plus maze, and  forced swimming test; (3) 
administration of  CBD with neurotransmitter receptor antagonists to confirm the action of 
CBD, such as WAY100635 antagonist of 5-HT1A receptors; and (4) investigations of other 
genes associated with anxiety, such as 5-HTT, 5-HT1A, and MAOA, to improve the 
67 
 
understanding of CBD as an anxiolytic therapeutic. Ultimately, the findings of this study 
contribute to understanding the pharmacological and neurological effects of CBD on the brain 
and its mechanism of action in the management of neurological disorders. 
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Figure 18: Precursor and product ion [M+H]+ mass spectra of cannabidiol. 
 
 
Figure 19: Precursor and product ion [M+H]+ mass spectra of dopamine. 




Figure 20: Precursor and product ion[M+H]+ mass spectra of GABA 
 
 
Figure 21: Precursor and product ion [M+H]+ mass spectra of glutamate. 
 
 








Figure 23: Precursor and product ion [M+H]+ mass spectra of serotonin. 
 
 


















Figure 25: : Quantifier and confirming ion chromatograms of (A) dopamine, (B) 
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Science in 2018 under the approved ethical clearance number (AREC 040 018 H). I have 
attended the Animal Ethics Training course presented by University of Kwa-Zulu Natal’s 
Biomedical Resource Unit (2018) which entailed: Introduction to laboratory animal sciences. 
Bioethics and Animal experimentation. Animal Research Methodology. Experimental design, 
environmental enrichment and occupational safety. I have successfully completed the Animal 
Handling course presented by the BRU.  
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 *N.B. If ALL of your work involving animals is performed at a Non-University of 
KwaZulu-Natal Centre, you need not complete the rest of this form, but you HAVE TO 
attach a letter of ethical approval obtained from the relevant authority at the Non-
University of KwaZulu-Natal Centre. 
6. BACKGROUND, OBJECTIVES AND POTENTIAL BENEFITS OF THE PROJECT 
 (Please give a clear and succinct statement of the background, objectives and potential benefits of 
the project under three separate headings - 3 pages allocated for this section including references) 
Background 
The plant, Cannabis sativa, comprises of more than 400 compounds, of that at least 
60 are cannabinoids which mediate its wide range of effects (Atakan, 2012). Delta- 9 
– tetrahydrocannabinol (THC) and cannabidiol (CBD) are the main phytocannabinoids 
which are the most commonly researched (Huestis, 2007). Cannabidiol (CBD) is the 
main non-psychoactive constituent and is reported to have both therapeutic and 
adverse effects (Alexander, 2016). The pharmacological action of CBD is elicited 
through the binding of these compounds to the cannabinoid-1 receptor (CB1) and 
cannabinoid-2 receptors (CB2), which are located in the cannabinoid system (Boggs 
et al., 2016). The CB1 receptors are primarily expressed in the central and peripheral 
nervous system, as well as in the heart, bones, lung, thyroid liver, uterus, testicular 
tissue and the vascular endothelium (Pertwee, 2006; Russo and Guy, 2006). CB1 
receptors are located at the GABAergic terminals and on glutamatergic terminals of 
the central and peripheral neurons and, in the central nervous system of the brain 
areas that are related to the body’s’ stress response (Atakan, 2012; Kaur and Singh, 
2016). These brain areas include the central amygdala, basal ganglia, limbic system, 
hippocampus, frontal cortex, substantia nigra and the cerebellum (Pertwee, 2006). 
Cannabinoid-2 receptors are mainly expressed in the gastrointestinal system, immune 
cells and spleen, and are also expressed at low levels in the central and peripheral 
nervous system (Pertwee, 2006).   
 
In the brain, CB1 receptors mediate inhibitory actions by the ongoing release of 
excitatory and inhibitory dopaminergic, gamma-aminobutyric acid (GABA), 
glutamatergic, serotoninergic, noradrenalin and acetylcholine neurotransmitter 
systems (Atakan, 2012). The involvement of the neurotransmitter systems 
subsequently affects functions such as pain perception, memory, cognition and motor 
movements (Howlett et al., 2002). Cannabis influences the activities of 
neurotransmitters in the brain, as GABA, glutamate and dopamine are generally higher 
in rats treated with cannabis (Owolabi et al., 2017). Cannabidiol (CBD) has complex 
pharmacological mechanisms of action involving neurotransmitter systems and 
receptors. Most of the evidence suggests that CBD reduces many of the psychoactive 
effects of THC (Morgan et al., 2012; Boggs et al., 2016). Recent literature has 
described the anxiolytic and antipsychotic properties of CBD (Atakan, 2012; Deepak 
et al., 2012). A study performed by Owolabi et al. (2017) investigated the relationship 
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in the modifications in neurotransmitter levels and enzymes caused by cannabis 
exposure in rats. The findings of this study reported that higher doses of CBD can 
potentiate the lower doses of d-9-THC by increasing the level of expression of CB1 
receptor in the hippocampus and the hypothalamus (Owolabi et al., 2017).  
 
In addition to cannabis-induced neurotransmitter modifications, the global increase in 
cannabis legalization has resulted in evolving scientific interest on the impact of 
cannabis on epigenome modification (Dobs and Ali, 2019). Epigenetics can be defined 
as the process that alters gene regulation, without changes in the DNA sequence, that 
may result in a specific phenotype (Berger et al., 2009). Molecules, that influence gene 
constitution, can express or supress genes if frequently exposed to a stimulus such as 
cannabis (Dobs and Ali, 2019).   
There remains a need to supplement the available literature related to the neural effect 
of Cannabis use on behavioural changes, with the accompanying in situ 
neurochemical and biochemical changes (Owolabi et al., 2017). There are gaps in the 
knowledge of the pharmacokinetics and behavioural effects of THC and CBD, as well 
as its combination, across the various administration forms (Hlozek, et al., 2017). The 
dose effects of cannabinoids in vivo against in vitro have not been fully described 
(Hlozek et al., 2017). There are many unanswered questions relating to the use of 
epigenetics in cannabis use disorders and the extent of epigenetic modifications (Dobs 
and Ali, 2019). The outcome of cannabis exposure to adolescents and adults is 
unknown due to the limited knowledge pertaining to cannabinoid-mediated epigenome 
modulations (Dobs and Ali, 2019).  
This study aims to investigate the effect of cannabinoids on the neurotransmitters in 
the brain.  
AIM: 
1. To determine the concentration of cannabidiol in the brain  
2. To evaluate the effect of cannabinoids on neurotransmitters in the brain 
3. To investigate the impact of cannabinoid exposure on epigenome modulation  
OBJECTIVES: 
1. To utilize LC-MS to quantify cannabidiol concentration in the brain 
2. To identify the epigenetic biomarkers associated with cannabis exposure using 
Western Blots and PCR  
POTENTIAL BENEFITS: 
Recently, cannabidiol has been punted as a solution to many neuropsychiatric 
disorders including anxiety, depression, epilepsy and panic disorders. 
Neurotransmitters are implicated in the pathogenesis of these disorders, but this has 
not been substantiated with scientific evidence. This study will understand the role of 
CBD and its effects on neurotransmitters in the brain. This can be potentially used in 
studies to develop novel therapeutic strategies for mental health disease as well as 
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7. DESCRIPTION OF YOUR PLAN OF WORK
 (Read the notes on this section – Apart from detail description, a mandatory flow diagram of 
experimental design to be attached in separate sheets, 4 pages allocated for this section including 
references) 
7.1. Source of Animals 
The Sprague-Dawley rats are sourced from the University of KwaZulu-Natal (Westville 
campus). The animal requisition process has been established within the BRU and 
there will be random selection of the animals.  
7.2. Animal care: 
The animals will be provided with commercially pelleted food and clean water ad 
libtium. The well-being of the animals, as well as the food and water supplies, will be 
overseen by the facility veterinarian and laboratory supervisor including weekends and 
vacation periods. The animal holding area is visited daily by a registered veterinarian. 
7.3. Housing and enrichment  
The animals will be collected two weeks prior to the procedure to allow for 
acclimatization. The rats will be weighed to confirm that they weigh 110 – 120g. The 
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animals will be housed in well-ventilated cages, located in temperature and humidity-
controlled housing units. Environmental enrichment, in the form of shredding paper 
and plastic tunnels, will be added to the cage.  
7.4. Reagents 
Cannabidiol will be administered via intraperitoneal injection at a dose of 10mg/kg 
body weight, which is reported to have no toxic effect on the animal according to 
literature. A chronic cannabinoid exposure study by Long et al. (2010) effectively 
administered cannabidiol in a saline solution vehicle, via intraperitoneal injection, at 
doses of 1, 5, 10 and 50 mg/kg body weight. Dieana et al. (2012) successfully 
intraperitoneally injected cannabidiol at a dose of 120 mg/kg body weight. The dose 
was based on the maximal concentration of cannabidiol that can be diluted in solvent 
(Dieana et al., 2012). There was no reported drug toxicity in both studies. Studies 
have shown that CBD administration causes slight sedation and slowed motor 
movements. CBD administration has not reported adverse psychological or 
cardiovascular effects.  
 
 
7.5. Drug treatment  
The animals will be treated with 10mg/kg body weight of pure cannabidiol which will 
be suspended in a 1:1:18 mixture of ethanol: Tween 80: saline (Long et al., 2010). A 
volume of 1ml/ 250g body weight will be administered via intraperitoneal injection to 
the animals in both the acute and chronic group. There are number of preclinical 
studies which have administered cannabinoids (d-9-tetrahydrocannabinol and 
cannabidiol) via intraperitoneal injection (Wiley et al., 2007; Long et al., 2010; Dieana 
et al., 2012; Taffe et al., 2015).  
 
Number of animals  Cannabinoid exposure Route of administration 
27 Acute  Intraperitoneal injection  
18 Chronic  Intraperitoneal injection  
7.6. Humane endpoints 
A humane endpoint sheet (attached) will be used to record the well-being of the 
animals for each experiment and kept on file. If any animal appears to be in severe 
discomfort prior to the experimental time point, that animal must be euthanized. 
Animals will be monitored twice daily. Should an animal display a sign of discomfort or 
abnormal behaviour, the supervising vet (Dr S. Singh. SAVC registration number DA 
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93/3378 ) will be consulted and deem if necessary, to euthanize the animal. This will 
then be formally reported to AREC via the Adverse Events Form.  
 
7.7. Study design 
Forty-five male Sprague-Dawley rats (110-120g) will receive 10mg/kg body weight via 
intraperitoneal injection. The animals will be randomly selected and assigned to the 
specified groups. The rats will be housed in polycarbonate cages, with a cage density 
of 646cm2. There will be 15 cages with 3 rats per cage: 9 cages will be used for the 
acute treatment and 6 cages will be used for the chronic treatment.  
The quantification of cannabidiol in the brain will be determined after acute and chronic 
dosing plans. This will allow the quantification of cannabidiol as well as its effect on 
the neurotransmitters at different time points following various lengths of exposure. 
The time intervals were determined based on previous pharmacokinetic studies 
involving cannabidiol (Deiana et al., 2011).  
Acute: the quantification of cannabidiol will be determined at intervals of 0, 15, 30, 60, 
120, 240, 360, 480 minutes and 24 hours. 
Chronic: the quantification of cannabidiol will be determined at intervals of 0, 7, 14, 
21 and 28 days.  
A. Acute exposure  
Each Sprague-Dawley rat will be intraperitoneally administered a single dose of 
10mg/kg cannabidiol. Three rats will be terminated from the acute group at the 
respective time interval (table 1), to determine the concentration of cannabinoids in the 
brain tissue and its effect on the neurotransmitters.  
 
Table 4: Acute exposure group and the number of animals to be terminated at the 
time points of euthanasia.  
Group Time points after administration (minutes) Number of rats 
 0 15 30 60 120 240 360 480 24hr  
Acute 3 3 3 3 3 3 3 3 3 27 
 
B. Chronic exposure 
Each Sprague-Dawley rat will be intraperitoneally administered a daily dose of 
10mg/kg cannabinoid, 6 days of the week. Three rats will be terminated from the 
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chronic group at the respective time interval (table 2), to determine the concentration 
of cannabinoids in the brain tissue and its effect on the neurotransmitters.   
 
Table 5: Chronic exposure group and the number of animals to be terminated at the 
time points of euthanasia. 
Group Time points after administration (days) Number of rats  
 0 7 14 21 28 28 
 (control)  
 
Chronic 3 3 3 3 3 3 18 
 
7.8. Euthanasia  
The animals will be euthanized by isoflurane overdose followed by cardiac puncture to 
collect blood. The blood will be collected in heparin tubes. The carcass will be disposed 





Isoflurane will be utilized as an anaesthetic, which will be administered to the animals prior 
to intraperitoneal injection to reduce any discomfort and pain caused to the animals.  
 
7.10. Tissue Harvest  
Following euthanasia of the animal, the brain tissues will be removed from the animal.  
The brain tissue will be cooled on ice for 15 minutes, before gradually freezing using 
liquid nitrogen vapour. Tissues will be stored at -80ºC until analysis. The carcass will 
be disposed of in an appropriate bag, which will be disposed by the BRU according to 
suitable disposal procedures. 
  
7.11. Analysis of tissue samples 
The analysis will be performed using Liquid chromatography-Mass Spectrometry, in 
combination with Bruker QTOF-II (Bruker Daltonics, Bremen, Germany), to quantify the 
concentration of cannabidiol in the brain, as well as the neurotransmitters, in both the 




Deiana, S., Wantanabe, A., Yamasaki, Y., Amada, N., Arthur, M., et al., 2012. Plasma and brain 
pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ9-
tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and 
intraperitoneal administration and CBD action on obsessive–compulsive behaviour. 
Psychopharmacology, 219: 859 – 873.  
Hložek, T., Uttl, L., Kadeřábek, L., Balíková, M., Lhotková, E., Horsley, R.R., Nováková, P., 
Šíchová, K., Štefková, K., Tylš, F., Kuchař, M., Páleníček, T. 2017. Pharmacokinetic and 
behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and 
subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC. 
European Neuropsychopharmacology, 27: 1223 – 1237.  
Long, L.E., Chesworth, R., Huang, X., McGregor, I. S., Arnold, J. C., Karl, T. 2010. A behavioural 
comparison of acute and chronic Δ9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. 
The International Journal of Neuropsychopharmacology, 13: 861 – 876.   
Taffe, M.A., Creehan, K. M., Vandewater, S. A. 201. Cannabidiol fails to reverse hypothermia or 
locomotor suppression induced by Δ9‐tetrahydrocannabinol in Sprague‐Dawley rats. British 
Journal of Pharmacology, 172(7): 1783- 1791. 
Wiley, J.L., O’Connell, M.M., Tokarz, M.E., Wright, M. J. Jr. 2007. Pharmacological Effects of 
Acute and Repeated Administration of Δ9-Tetrahydrocannabinol in Adolescent and Adult Rats. 
The Journal of Pharmacology and Experimental Therapeutics, 320: 1097 – 1105.  
 
 
8. INDEX OF PROCEDURES 
Consult the Approved Standard Protocols Booklet (available from the Research office 




8.1  Experimental procedures (other than antibody production-see Table 8.2) included in the 
Approved Standard Protocols Booklet: Using the Approved Standard Protocols Booklet, 
note by title and code the protocols to be used for each of the experimental procedures 
other than antibody production in your proposed studies. 
 
Species1 Rat     
Strain Sprague-
Dawley 
    
Age/weight 110-120g     
Sex Male     
Number of animals  45     
Handling (code) RH 
 





Code(s) for procedure(s) RIIP 
 
 
    




    




    
Name of anaesthetic/ analgesic Isoflurane  
 
    








8.2  Antibody production:  Antibody production follows the general format of animal handling, 
immunisation, bleeding and eventually euthanasia, with each researcher using a number 
of unique schedules. To expedite review, use the Approved Standard Protocols Booklet 
code numbers and simply indicate the species, route of injection, total number of injections, 
type of adjuvant, method of bleeding, including volume and frequency, and method of 
euthanasia. 
Species1      
Strain      
Age/weight      
Sex      
Number of animals/immunogen      
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Total number of immunisations      
Adjuvant(s)       




    
Blood volume      
Bleeding frequency      




    
List of immunogens to be used: 
 
 
Will non-physiological, unusually painful, or harmful material be injected?  If so, explain and 







 8.3  Experimental procedures NOT included in the Approved Standard Protocols Booklet. Please 
give details of all procedures using the same format as that in the Booklet.  Please use 
additional sheets if necessary. 
 






9. What is your assessment of the overall severity of this project? 
 Please tick in one box only to indicate your assessment. 
 
  Substantial  
  Moderate 
  Mild 





9.1  Have all surgical and non-surgical procedures been clearly and completely described, 
consistent with the experimental design outline? – Explain briefly. 




9.2 Has pain, discomfort and distress to the animal(s) been minimized or avoided to the fullest 
extent possible? – Explain briefly. 
Yes, the experimental design has been developed with the 3R’s in consideration.  
Replacement: This study will investigate the effect of cannabinoids on the neurotransmitters in the 
brain, as well as the related epigenetic changes. Therefore, the use of animals in this project cannot 
be replaced as the changes in neurotransmitters cannot be observed using cell cultures or cell lines. 
There were efforts made to reduce the number of animals and refine the protocol whilst ensuring the 
number of animals per group can be used for statistical analysis  
 
Reduction: To reduce the number of animals used, the LC-MS will be conducted by utilizing half of 
the cerebral hemisphere, and the other half will be used to conduct epigenetic tests, instead of 
sacrificing a single animal for each experimental analysis. 
 
Refinement: The rats will be injected with a 27-gauge needle to reduce pain and discomfort 
experienced by the animal. The chronic treatment will be administered 6 days a week, allowing one 
day for the recovery and rest of the animal During the chronic treatment, there will be swapping of the 
peritoneum sides during intraperitoneal injection to minimize discomfort to the animal.  Environmental 
enrichment, in the form of shredding paper and/or plastic tunnels, will be added to the cages to 
minimize stress caused to the animal. Upon termination, the animals will be euthanized by an 
isoflurane overdose, before collecting tissue samples, thereby preventing pain and discomfort to the 
animal.  
 
9.3 Is there any appropriate plan for monitoring animals for pain, discomfort and distress, including 
criteria for determining early euthanasia (humane endpoint)? – Explain briefly. 
 
Yes, the humane endpoint form is attached to the application to record the well-being of the animal 










SUBMISSION CHECK LIST (Click on the appropriate boxes to complete) 
 
  YES NO N/A 
1 Is your supervisor’s (if not self-supervised) progress reports for 
all applications / renewals approved since January 2017 up to 
date (if applicable)? 
☒ ☐ ☐ 
2 Are the contact details of the applicant and main supervisor 
supplied?  
☒ ☐ ☐ 
3 Are the members of the research team qualified and 
experienced in the procedures to be performed?  
☒ ☐ ☐ 
4 Are the PROOFs of animal training for main applicant 
(mandatory) and other members in the application enclosed as 
mentioned in section 3? 
☒ ☐ ☐ 
5 Is a clear and succinct statement of the background, objectives 
and potential benefits of the project given under section 6? 
☒ ☐ ☐ 
6 Are all housing, feeding, surgical and non-surgical procedures 
clearly and completely described, and are they consistent with 
the experimental design? 
☒ ☐ ☐ 
7 Is there adequate statistical or technical justification provided 
for the number of requested animals? 
☒ ☐ ☐ 
8 Are the following mandatory items attached to the application 
form? 
a) a complete flow diagram of experimental design;  
b) a humane endpoint form / table specific to you project. 
☒ ☐ ☐ 
9 Have you discussed your experimental design with an expert 
animal facility staff/technician? 
☒ ☐ ☐ 
10 Have you obtained all necessary permits for your experimental 
procedures? 
☐ ☐ ☒ 
11 Do you need a provisional approval letter from AREC to apply 
for any permits/site approval? 
☐ ☒ ☐ 
12 Has scientific content of the application been thoroughly 
reviewed by your supervisors (if applicable)? (mandatory for all 
application submitted by postgraduate students and 
postdoctoral / research fellows) 
☒ ☐ ☐ 
13 Are all sections of the applications completed and signed by all 
parties? 





10. DECLARATION BY THE APPLICANT AND HEAD OF SCHOOL 
 I have considered the feasibility of achieving the purpose of the project by means other than 
those using animals and, in my opinion, no such alternatives would achieve the objectives 
of this project. I agree to follow the Approved Standard Protocols Booklet and any delineated 
modifications as approved by the Animal Ethics Sub-committee.  I will also supervise and 
assure compliance and training by my co-workers and students as listed above. 
 
 
  ____________________________    
   SIGNATURE OF APPLICANT DATE 
 
 
 __________________________________  
                 INITIALS & SURNAME OF SUPERVISOR*  
     (Please complete – required for mailing copy of approval letter.) 
 
 
  _________________________________  _______________________ 
    SIGNATURE OF SUPERVISOR*        DATE 
  
 
  ____________________________________  
               INITIALS & SURNAME OF D&HoS / ALR  
     (Please complete – required for mailing copy of approval letter.) 
 
 
 __________________________________         _______________________ 
        SIGNATURE OF D&HoS / ALR                    DATE 
 
*Name and signature of supervisor required if application submitted by postgraduate & postdoctoral students 
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